

**University of Alberta**

**Differential Neurotrophic Regulation of Sodium and Calcium Channels in Adult Sympathetic Neurons**

**by**

**Kenneth V. Wong**



**A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science**

**Centre for Neuroscience  
Edmonton, Alberta  
Spring 2008**



Library and  
Archives Canada

Published Heritage  
Branch

395 Wellington Street  
Ottawa ON K1A 0N4  
Canada

Bibliothèque et  
Archives Canada

Direction du  
Patrimoine de l'édition

395, rue Wellington  
Ottawa ON K1A 0N4  
Canada

*Your file* *Votre référence*

*ISBN: 978-0-494-45909-6*

*Our file* *Notre référence*

*ISBN: 978-0-494-45909-6*

**NOTICE:**

The author has granted a non-exclusive license allowing Library and Archives Canada to reproduce, publish, archive, preserve, conserve, communicate to the public by telecommunication or on the Internet, loan, distribute and sell theses worldwide, for commercial or non-commercial purposes, in microform, paper, electronic and/or any other formats.

The author retains copyright ownership and moral rights in this thesis. Neither the thesis nor substantial extracts from it may be printed or otherwise reproduced without the author's permission.

**AVIS:**

L'auteur a accordé une licence non exclusive permettant à la Bibliothèque et Archives Canada de reproduire, publier, archiver, sauvegarder, conserver, transmettre au public par télécommunication ou par l'Internet, prêter, distribuer et vendre des thèses partout dans le monde, à des fins commerciales ou autres, sur support microforme, papier, électronique et/ou autres formats.

L'auteur conserve la propriété du droit d'auteur et des droits moraux qui protègent cette thèse. Ni la thèse ni des extraits substantiels de celle-ci ne doivent être imprimés ou autrement reproduits sans son autorisation.

---

In compliance with the Canadian Privacy Act some supporting forms may have been removed from this thesis.

Conformément à la loi canadienne sur la protection de la vie privée, quelques formulaires secondaires ont été enlevés de cette thèse.

While these forms may be included in the document page count, their removal does not represent any loss of content from the thesis.

Bien que ces formulaires aient inclus dans la pagination, il n'y aura aucun contenu manquant.



**Canada**

## Abstract

Electrophysiology studies from our laboratory have examined regulation of ion channels by NGF and LHRH. Our laboratory found that 1) Exposure of BFSG to NGF in defined-serum-free media upregulates  $\text{Na}^+$  current as well as both N- and L-type  $\text{Ca}^{2+}$  currents. 2) LHRH also upregulates  $\text{Ca}^{2+}$  currents, but does not affect  $\text{Na}^+$  current. 3) LHRH appears to increase  $\text{Ca}^{2+}$  current via the MAPK pathway; 4) this effect may be mediated via PKC and PKA is necessary but not sufficient to affect the transduction process. 5) NGF increases  $\text{Na}^+$  currents via the PI3K pathway. The studies presented in this thesis support and extend the above findings. I found that 1) LHRH signals via Ras-MAPK and not by Rap-1 to increase  $I_{\text{Ca,N}}$ ; 2) this effect is mediated via  $\text{PKC}\beta\text{II}$ . The immunoblot studies confirm that 1) PKA is necessary but not sufficient to effect transduction; 2) NGF signals via PI3K to increase  $I_{\text{Na}}$ .

## Acknowledgment

First, I must thank my supervisor Dr. Peter Smith for knowledge, guidance, and support through out the course of my MSc study.

To my co-supervisor Dr. Elena Posse de Chaves, I thank her for her valuable inputs, guidance, and also keeping me on track throughout my study. My project would not have been without her help.

I would also like to thank Dr. Kathryn Todd for being my Neuro 501 supervisor as well my examining committee member.

To Mee-Sook Song, Valeria Mancinelli, and Lucila Saavedra, I must thank them for teaching me Western blotting.

To Chris Ford, I thank him for his electrophysiology data and to Van Lu, I thank her also for her electrophysiology data, as well as, for teaching me how to set up and maintain the organotypic cultures.

To Pat Stenskowski, I thank him for teaching me the frog dissection as well as being a persistent gym buddy. To Kwai Alier, I thank him for his tips on immunoprecipitation, MAPK, and all the unforgettable TGIFs. Also, to Sridhar, I thank him for his input on my thesis proposal and also for going to the gym with me.

Finally, but definitely not least, I must thank my family: my parents Harley and Kimberly for their endless love and support; my wife May for her love, patience, and constant encouragement to reach my goals; and my “bundle of joy” Charlene, she is my sunshine!

## Table of Contents

<b>Chapter 1 General Introduction.....</b>	<b>2</b>
1.1 Introduction.....	2
1.2 BFGS organization.....	5
1.3 BFGS B-neuron ion channels.....	6
1.4 Neurotrophic factors.....	8
1.4.1 Neurotrophins.....	8
1.4.2 Nerve growth factors (NGF).....	9
1.4.3 Glial-cell-line-derived neurotrophic factor (GDNF).....	11
1.5 Phosphatidylinositol-3-kinase (PI3K).....	12
1.6 Luteinizing hormone releasing hormone (LHRH).....	14
1.6.1 LHRH.....	14
1.7 Signal transduction of G-protein coupled receptors.....	16
1.7.1 Properties of G-protein coupled receptors (GPCRs).....	16
1.7.2 Phospholipase C (PLC).....	22
1.7.3 Protein kinase C (PKC).....	22
1.7.4 Protein kinase A (PKA).....	24
1.7.5 Mitogen-activated protein kinase (MAPK).....	25
1.7.6 Extracellular-regulated kinase (Erk).....	26
Statement of Problem.....	28

<b>Chapter 2 Methodology.....</b>	<b>32</b>
2.1 Methods.....	32
2.1.1 Cell culture.....	32
2.1.2 Chemicals.....	32
2.1.3 Morphology analysis.....	33
2.1.4 Immunoblot analysis.....	34
2.1.5 Ras activation assay.....	36
2.1.6 Rap-1 activation assay.....	37
2.2 Quantification.....	38
<b>Chapter 3 Results.....</b>	<b>40</b>
3.1 Results.....	40
3.1.1 Mechanism of LHRH induced increase of $I_{Ca}$ .....	40
3.1.2 How do LHRH receptors couple to MAPK?.....	43
3.1.3 Mechanism of NGF-induced increase in $I_{Na}$ .....	45
3.1.4 Does LHRH activate Akt?.....	46
3.1.5 LHRH effect is independent of neurite outgrowth.....	47
<b>Chapter 4 Discussion and Future Directions.....</b>	<b>63</b>
4.1 Discussion.....	63
4.1.1 Role of Ras-MAPK in the LHRH induced increase in $I_{Ca}$ .....	64
4.1.2 Role of PI3K in NGF induced increase in $I_{Na}$ .....	68
4.1.3 LHRH effect is independent of neurite outgrowth.....	69

4.1.4 Lack of effect of LHRH on Na <sup>+</sup> currents.....	69
4.2 Future Directions.....	71
<b>References.....</b>	<b>74</b>

## List of Figures

Figure 1.....	30
Figure 2.....	49
Figure 3.....	50
Figure 4.....	51
Figure 5.....	52
Figure 6.....	53
Figure 7.....	54
Figure 8.....	55
Figure 9.....	56
Figure 10.....	57
Figure 11.....	58
Figure 12.....	59
Figure 13.....	60
Figure 14.....	61
Figure 15.....	73



## List of Tables

Table 1 .....	48
---------------	----

## List of Abbreviations

AC.....	adenyl cyclase
Ach.....	achetylcholine
Akt.....	protein kinase B
AP.....	action potential
ARTN.....	artemin
BDNF.....	brain-derived neurotrophic factor
BFSG.....	bullfrog sympathetic ganglia
B-Raf.....	B-type MAPK kinase kinase
Ca <sup>2+</sup> .....	calcium
cAMP.....	Adenosine-3', 5'-cyclic mononphosphate
CaaX.....	carboxyl terminal motif with two aliphatic residues
CAM Kinase II.....	calmodulin kinase type 2
CDC42.....	cell division cycle 42
CNS.....	central nervous system
CREB.....	cAMP response element-binding protein
C-terminus.....	carboxyl terminal
DAG.....	1, 2-diacyglycerol
DH.....	Dbl-homology
DMSO.....	dimethyl sulfoxide
DNA.....	deoxyribonucleic acid
ECL Plus.....	enhanced chemiluminescence plus
EDTA.....	ethylenediamine tetraacetic acid

EGTA.....ethylene glycol tetraacetic acid

Epsp.....excitatory post-synaptic potential

ERK.....extracellular-regulated kinase

FPA124.....PKB inhibitor

FSH.....follicle-stimulating hormone

G<sub>i</sub>.....alpha i/o subunit of G-protein

G<sub>α12/13</sub> .....alpha 12/13 subunit of G-protein

G<sub>q/11</sub>.....alpha q/11 subunit of G-protein

G<sub>s</sub>.....alpha s subunit of G-protein

Gβγ.....beta gamma subunit of G-protein

GABA.....γ-aminobutyric acid

GAP.....GTPase activating proteins

GDI.....guanine nucleotide dissociation inhibitor

GDNF.....glial-cell-line-derived neurotrophic factor

GDP.....guanosine diphosphate

GEF.....guanine-nucleotide exchange factor

GFLs.....(GDNF) family ligands

GFRα.....type α GDNF family receptor

GFRα1.....type α1 GDNF family receptor

GFRα2.....type α2 GDNF family receptor

GFRα3.....type α3 GDNF family receptor

GFRα4.....type α4 GDNF family receptor

GnRH.....gonadotropin-releasing hormone

GPCR.....G-protein coupled receptor

GRF.....guanine-releasing factor

GRK.....G-protein receptor kinase

GRP.....Ras guanylnucleotide-releasing protein

GST.....glutathione S transferase

GST-RBD.....GST fused to Ras binding domain of Raf1

GTP.....guanosine triphosphate

GTPase.....guanosine triphosphatase

GTP- $\gamma$ -S.....guanosine triphosphate gamma S

H-89.....N-[2-(p-Bromocinnamylamina)ethyl]-5-  
isoquinolinesulfonamide-2HCl

$\alpha$ -HFA..... $\alpha$ -Hydroxyfarnesylphosphonic acid

HPLC.....high performance liquid chromatography

H-Ras.....H-type MAPK kinase kinase

$I_A$  .....A-current

$I_{AHP}$  .....slow voltage-insensitive calcium-sensitive potassium current

$I_C$ .....fast voltage-sensitive calcium-sensitive potassium current

$I_K$  .....delayed rectifier potassium current

$I_M$  .....slow-activating non-inactivating muscarinic-sensitive  
potassium current

IP<sub>3</sub>..... inositol 1, 4, 5-triphosphate

JNK/SAPK.....c-Jun-N-terminal kinase/stress-activated protein kinase

K<sup>+</sup>.....potassium

kDa.....kilo-Dalton

K-Ras.....K-type MAPK kinase kinase

LH.....luteinizing hormone

LHRH.....luteinizing hormone releasing hormone

LHRH-R.....luteinizing hormone releasing hormone receptor

LY294002.....PI3K inhibitor

MAPK.....mitogen-activated protein kinase

MEK.....mitogen-activated protein kinase kinase

Na<sup>+</sup> .....sodium

NaCl.....sodium chloride

Na<sub>2</sub>VO<sub>4</sub>.....sodium orthovanadate

NaF.....sodium fluoride

NGF.....nerve growth factor

NH<sub>2</sub>.....amino acid terminal

N-Ras.....N-type MAPK kinase kinase

NRTN.....neurturin

NT-3.....neurotrophin-3

NT4/5.....neurotrophin-4/5

NT-6.....neurotrophin-6

NT-7.....neurotrophin-7

p38 MAPK.....p38 type mitogen-activated protein kinase

p75.....p75 type neurotrophin receptor

p90-RSK.....p90- ribosomal S6 kinase

PA.....perillic acid

Pac1.....PACAP receptor

PACAP.....pituitary adenylate cyclase-activating polypeptide

PAGE.....polyacrylamide gel electrophoresis

PC12.....pheochromocytoma cell 12

PD98059.....2'-amino-3'-methoxyflavone

PDGF.....platelet-derived growth factor

PDK1.....3-phosphoinositide-dependent kinase

PH.....pleckstrin-homology

PI.....phosphoinositol

PI-3-P.....phosphatidylinositol-3-monophosphate

PI-3, 4-P2.....phosphatidylinositol-3,4-bisphosphate

PI-3, 4, 5-P3.....phosphatidylinositol-3, 4, 5-triphosphate

PI-4-P.....phosphatidylinositol-4-monophosphate

PI-4, 5-P2.....phosphatidylinositol-4, 5-bisphosphate

PI3K.....phosphatidylinositide-3-kinase

PI-PLC.....phosphoinositide-specific phospholipase C

PKA.....protein kinase A

PKB.....protein kinase B

PKC.....protein kinase C

PLC.....phospholipase C

PMA.....phorbol 12-myristate-13-acetate

4 $\alpha$  PMA.....4 alpha phorbol 12-myristate-13-acetate

PSPN.....persephin

PTB.....phosphotyrosine-binding

PVDF.....‘Immobilin’ polyvinylidene difluoride

PyK2.....proline-rich tyrosine kinase 2

Raf-1.....MAPK kinase kinase

Rap1.....Repressor activator protein 1

Ras.....MAPK kinase kinase kinase

Rp-cAMPS.....Rp-Adenosine-3', 5'-cyclic mononphosphorothioate  
triethylamine salt

RTKs.....receptor tyrosine kinases

SDS.....sodium dodecyl sulfate

SfN .....Society for Neuroscience

SH-2.....src-homology-2

Sp-cAMPS.....Sp-Adenosine-3',5'-cyclic mononphosphorothioate  
triethylamine salt

STX.....saxitoxin

TBS.....tris-buffered saline

TGF- $\beta$ .....transforming growth factor- $\beta$

TM.....transmembrane

7TM.....seven transmembrane

Trk.....tropomyosine-related kinase

TrkA.....tropomyosine-related kinase A

TrkA<sub>II</sub>.....tropomyosine-related kinase A type II

TrkB..... tropomyosine-related kinase B  
Trk C.....tropomyosine-related kinase C  
TTBS.....tween-20 tris-buffer saline  
TTX.....tetrodotoxin  
U73122.....PLC inhibitor  
UV.....ultra-violet  
VGCC.....voltage-gated calcium channel  
Y490.....tyrosine residue 490  
Y670.....tyrosine residue 679  
Y674.....tyrosine residue 674  
Y675.....tyrosine residue 675  
Y785.....tyrosine residue 785  
Y905.....tyrosine residue 905  
Y1015.....tyrosine residue 1015  
Y1062.....tyrosine residue 1062  
Y1096.....tyrosine residue 1096



**Chapter 1**  
**General Introduction**

## 1.1 Introduction

Appropriate neuronal phenotypic expression is essential for proper functioning of the nervous system. Although the genetic makeup of each organism supplies the foundation for the nervous system, correct phenotypic expression of neurons is dependent on exogenous and endogenous signals. Classically neurotrophins are responsible for growth, development, and repair of the nervous system, whereas, neurotransmitters are thought to be primarily responsible for rapid communication between neurons. However, recent work has demonstrated that neurotrophins and neurotransmitters can act similarly in certain systems; hence, the division between their roles is becoming less distinct.

Neurotrophins can be released through an activity-dependent mechanism (Balkowiec and Katz, 2002), which can modulate synaptic transmission as well as having acute non-trophic regulatory effects on ion channels. Acute application of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) has been shown to potentiate synaptic transmission via the Trk receptors (Lohof et al., 1993). Other studies have also demonstrated BDNF having direct regulation of various ion channels and also the release of glutamate (Levine et al., 1998; Takei et al., 1998; Yang et al., 2001). Hence, it appears that neurotrophin has two acute mechanisms of action 1) by regulating ion channels and 2) by regulating synaptic transmission. In addition, neurotrophins can trigger rapid generation of action potentials in a time course that is similar to classical neurotransmitters, further indicating that in certain systems neurotrophins can act similarly to traditional neurotransmitters (Kafitz et al., 1999; Kovalchuk et al., 2004; Blum and Konnerth, 2005).

Since neurotrophin receptors and G-protein coupled receptor (GPCR) are capable of activating comparable pathways, it is possible that GPCR agonists could regulate neuronal survival, growth, and differentiation. Pituitary adenylate cyclase-activating polypeptide (PACAP) has been demonstrated to induce differentiation and neurite outgrowth through an extracellular regulated kinase (Erk)-dependent but Ras-independent manner in pheochromocytoma (PC12) cells (Barrie et al., 1997; Lazarovici et al., 1998). Many neurotransmitters have also been shown to influence multiple aspects of neuronal maturation (Lauder, 1993; Cameron et al., 1998). For instance,  $\gamma$ -aminobutyric acid (GABA) has been shown to signal through the GABA<sub>B</sub> receptor to regulate nerve growth cone guidance (Xiang et al., 2002). Moreover, GABA has been shown to influence cell proliferation, dendritic growth, pre-synaptic specialization, and GABA receptor expression in various systems (Wolff et al., 1978; Redburn and Schousboe, 1987; Spoerri, 1988). These events have been attributed to increased L-type voltage-gated calcium channel (VGCC) activity leading to increased intracellular Ca<sup>2+</sup> level, activating immediate early genes such as: c-fos, jun-B, fos-C, and zif268, which trigger transcriptional events (Murphy et al., 1991). Further evidence for trophic action of neurotransmitters is from GnRH. GnRH is a classical neurotransmitter capable triggering a late slow excitatory post-synaptic potential (late slow epsp) in bullfrog sympathetic ganglia (BFSG) (Jan et al., 1979; Jan et al., 1980a; Jan et al., 1980b; Jan and Jan, 1982). Gonadotropin-releasing hormone also known as luteinizing hormone-releasing-hormone (LHRH) is known as a primary initiator of the hormonal cascade in the reproductive system (King and Millar, 1980). It triggers the synthesis and release of follicle-stimulating hormone and luteinizing hormone

from the anterior pituitary, after its release from the hypothalamus (Cheng and Leung, 2000; Klausen et al., 2002). GnRH also has neuroendocrine and neuromodulatory effects in the peripheral nervous system (Millar et al., 1987).

It is also known that neuronal phenotypes in the adult nervous system are defined by differential morphological, biochemical, and electrical properties. Expression of ion channels on a given neuronal type may change during development, maturation, injury or disease (Jassar et al., 1993; Jassar et al., 1994; Cummins and Waxman 1997; Lhuillier and Dryer 2002; Craner et al., 2002; Martin-Caraballo and Dryer, 2002). Hence, various neurotrophic factors have been studied in adult neurons and in cell lines to examine their critical roles in ion channel expression (Chalazonitis et al., 1987; Levine et al., 1995; Pollock et al., 1990; Pollock and Rane 1996; Fanger et al., 1997). Studies have shown that in B-neurons of adult bullfrog sympathetic ganglia (BFSG), target-derived nerve growth factor (NGF) is responsible for the maintenance of TTX-sensitive and TTX-insensitive sodium currents ( $I_{Na}$ ) and of N- and L-type calcium currents ( $I_{Ca,N}$  and  $I_{Ca,L}$ ) (Lei et al., 1997; Lei et al., 1998; Lei et al., 2001; Petrov et al., 2001). Furthermore, in serum-free, defined medium culture, NGF has been reported to induce increases in  $I_{Ca}$  and is mediated through the mitogen-activated protein kinase (MAPK) pathway (Lei et al., 1998), whereas, the transduction mechanism underlying the NGF-induced increases in  $I_{Na}$  remains to be unravelled. Interestingly, LHRH, a neurotransmitter released from preganglionic C-fibers in BFSG (Jan et al., 1979; Jan et al., 1980) is also able to regulate functional expression of  $Ca^{2+}$  channels (Ford et al., 2003a). Gonadotrophin receptors can couple

through  $G_{q/11}$ ,  $G_s$ , or  $G_i$  to various downstream substrates including Ras-MAPK (Sim et al., 1995; Naor et al., 1998b) to mediate their effects.

## 1.2 BFSG organization

All experiments in this thesis have been carried out on bullfrog paravertebral sympathetic ganglia (BFSG). Unlike the mammalian ganglia such as the dorsal root ganglia, which have many different neuronal subtypes (Lewin, 1996), the BFSG system has only two principal types of neurons that are easily identifiable in vitro based on physical size and consistent electrophysiological properties: large, exocrine B-neurons and smaller C-neurons. B-neurons project to targets in the skin and C-neurons project mainly to blood vessels (Adams et al., 1986; Horn et al., 1988; Jassar et al., 1993; Smith, 1994; Ivanoff and Smith, 1995; Jobling and Horn, 1996; Thorne and Horn, 1997).

Preganglionic B- and C- fibers originate from separate neuronal populations in the spinal cord and remain separate through the paravertebral ganglia (Nishi et al., 1965; Dodd and Horn, 1983a; Horn and Stofer, 1988). B-fibers emerge through roots IV<sup>th</sup>, V<sup>th</sup>, and VI<sup>th</sup>, whereas C-fibers emerge through roots VII<sup>th</sup> and VIII<sup>th</sup> (Libet et al., 1968; Horn and Stofer, 1988). Furthermore, adult BFSG neurons can be maintained in a serum-free, defined medium culture system for over 14 days (Lei et al., 1997). A serum-free, defined medium culturing system is free of complicating effects from exogenous neurotrophins allowing for the study of trophic actions of neurotransmitter. In BFSG LHRH is solely released from pre-ganglionic C-fibers (Jan

et al., 1979; Jan et al., 1980b; Jobling and Horn, 1996; Thorne and Horn, 1997) and diffuses to B-neurons, hence, is capable of influencing B-neurons by means of “volume” transmission.

### **1.3 BFG B-neuron ion channels**

Since the focus of this thesis is on the signalling pathways that may be responsible for Na<sup>+</sup> and Ca<sup>2+</sup> channel regulation in BFG, the properties of ion channels that have been characterized by others will be briefly discussed. The properties of voltage-dependent Na<sup>+</sup>, Ca<sup>2+</sup>, and various K<sup>+</sup> channels have been well studied on B-cells of BFG (Smith 1994).

The fast, voltage-activated Na<sup>+</sup> channel currents that are responsible to the upstroke of an action potential (AP) have been characterized in BFG cells (Jones, 1987).

Total Na<sup>+</sup> channel currents are comprised of two pharmacological and kinetic components. A large portion of the total current is tetrodotoxin (TTX) and saxitoxin (STX) sensitive that also activates and inactivates rapidly. A smaller portion of the total current is resistant to TTX but sensitive to STX and Cd<sup>2+</sup>. This also activates rapidly but inactivates 3-folds slower than the larger component (Lei et al., 2001).

Voltage-gated calcium channels (VGCC) in BFG are well characterized (Jones and Marks, 1989a, b; Jones and Jacobs, 1990; Sala, 1991; Werz et al., 1993). These channels also play critical roles in the generation of AP in BFG neurons (Pennefather et al., 1985; Smith, 1994). Activation and deactivation of these channels

are rapid (Jones and Marks, 1989a), whereas the inactivation kinetics are slower and more complex (Sala, 1991). VGCC are classified into four types: N-, P/Q-, R-, and L-type (Catterall, 2000). In BFG, N-type channels carry ~ 90% of the total  $I_{Ca}$ , whereas L-type channels carry most of the remaining amount (Jones and Elmslie, 1992). N-, P/Q-, and R-type channels are mainly responsible for  $Ca^{2+}$  entry into neurons to induce neurotransmitters release, whereas, L-type channels are mainly responsible for  $Ca^{2+}$  entry to initiate gene transcription and endocrine secretion (Catterall, 2000).

The various types of  $K^+$  channels that have been characterized in BFG are: M-current ( $I_M$ ); delayed rectifier  $K^+$  current ( $I_K$ ); fast, voltage-sensitive,  $Ca^{2+}$ -sensitive  $K^+$  current ( $I_C$ ); slow, voltage-insensitive,  $Ca^{2+}$ -sensitive  $K^+$  current ( $I_{AHP}$ ); and A current ( $I_A$ ).  $I_M$  is a slowly activating, non-inactivating, and muscarinic-sensitive  $K^+$  current (Brown and Adams, 1980; Adams et al., 1982a, 1986; Marrion et al., 1991).  $I_M$  is inhibited by nucleotides (Groul et al., 1981; Adams et al., 1982b; Tokimasa and Akasu, 1990), Acetylcholine (Ach) and LHRH (Adams and Brown, 1982; Jones et al., 1984; Jones, 1985), adrenoceptor agonists (Akasu, 1988; Selyanko et al., 1990a), and peptidergic agonists (Adams and Brown, 1982; Adams et al., 1982b, 1983; Jones, 1985; Pfaffinger et al., 1988; Bosma and Hille, 1989; Bley and Tsien, 1990). The physiological role of  $I_M$  may be to act as a voltage-clamp for cells to resist depolarizing stimulus influence (Adams et al., 1982a); therefore, suppression of  $I_K$  will give a powerful excitatory effect.  $I_K$  activates at potentials above -25mV and inactivates during long depolarizing events (Adams et al, 1982a) and is blocked by 3, 4-diaminopyridine (Goh et al., 1989). Although the physiological role of  $I_K$  is

unclear, one possible role is to control repetitive discharge when other  $K^+$  currents are antagonized (Goh et al., 1989).  $I_C$ , as the name suggests is a fast activating, voltage-sensitive,  $Ca^{2+}$ -sensitive  $K^+$  current (Adams et al., 1982a), which can be blocked by removal of extracellular  $Ca^{2+}$  or addition of  $Cd^{2+}$ . The physiological role of  $I_C$  is to repolarize action potentials and generate part of the afterhyperpolarization (AHP) (Adams et al., 1982c; Pennefather et al., 1985; Lancaster and Pennefather, 1987).  $I_{AHP}$  is a slow, non-inactivating, voltage-insensitive,  $Ca^{2+}$  sensitive  $K^+$  current (Marrion et al., 1991), which can be blocked by d-tubocurarine and apamin (Goh and Pennefather, 1987). The physiological role of  $I_{AHP}$  is to generate the latter portion of an AP afterhyperpolarization (Lei dissertation 1997).  $I_A$  is a rapid but transient outward  $K^+$  current (Adams et al, 1982a). Activation of this channel requires the removal of inactivation that normally occurs at resting potential (Lei dissertation 1997). The physiological role of  $I_A$  is still unclear to date.

#### **1.4 Neurotrophic factors**

Since the aim of this thesis is to examine the effect of NGF on  $Ca^{2+}$  and  $Na^+$  channel regulation, basic neurotrophin properties, particularly NGF, as well as its downstream effector PI3K will be discussed, the remaining effectors will be discussed in a later section. A brief discussion of glial-cell-line-derived neurotrophic factor (GDNF), a member of the second family of neurotrophic factors will also be included since studies have shown its involvement in sympathetic neuron survival and regulation.



### ***1.4.1 Neurotrophins***

Neurotrophins are a class of secretory proteins that are considered to be critical for neuronal survival, growth, and differentiation. Currently, six neurotrophins have been identified: NGF, BDNF, NT-3, neurotrophin-4/5 (NT4/5), neurotrophin-6 (NT-6), neurotrophin-7 (NT-7) (Hallbook, 1999). NT-6 and NT-7 have only been characterized in fish (Gotz et al., 1994, Nilsson et al., 1998). As to date, there are two known classes of neurotrophin receptors: the p75 receptor, which is non-selective, has equal affinity for all neurotrophins, and the second class Trk (tropomyosine-related kinase) receptor tyrosine kinase, which has high affinity for mature neurotrophins. Neurotrophins elicit their effects by binding to the high affinity Trk receptors that includes (TrkA, TrkB, and Trk C). NGF binds to TrkA, BDNF and NT-4/5 bind to TrkB, and NT-3 binds to TrkC (Chao, 1992). By contrast, all neurotrophins are able to bind competitively to the p75 receptor (Squinto et al., 1991).

Activation of Trk receptors results in dimerization of the receptors leading to autophosphorylation of the cytoplasmic domain tyrosine residues (Y490, Y785, Y670, Y674, Y675) (Stephens et al., 1994) on the receptors (Huang and Reichardt, 2001). Following intracellular tyrosine phosphorylation, adaptor proteins containing phosphotyrosine-binding (PTB) or src-homology-2 (SH-2) motifs are recruited to the receptor (Pawson and Nash, 2000). These adaptor proteins then couple Trk receptors to intracellular signalling cascades that include the Ras/ERK pathway, the phosphatidylinositide-3-kinase (PI3K/Akt) pathway, and the phospholipase C (PLC)- $\gamma$ 1 pathway (Reichardt and Farinas, 1997; Kaplan and Miller, 2000). Shc binding at Y490 acts as an adaptor for recruiting other proteins which lead to activation of the

Ras/Erk or PI3K pathways. PLC $\gamma$  binds at Y790 where it is activated and mediates its effects (Arevalo and Wu, 2006).

#### ***1.4.2 Nerve growth factor (NGF)***

NGF, the most studied neurotrophin, was discovered over 50 years ago as a molecule important in regulating neuron survival, development and maintenance of vertebrate nervous systems (Levi-Montalcini and Hamburger, 1951; Levi-Montalcini and Hamburger, 1953). The NGF gene is expressed as two splice variants (Edwards et al., 1986). The mature, biologically active form appears to be similar in all tissues, which consists of 13-kDa polypeptide chains (Sofroniew et al., 2001).

NGF mediates its effects through binding to its receptors, TrkA and p75 (Bothwell, 1995). The TrkA receptor features a single-pass transmembrane domain acting as a receptor for NGF (Loeb et al., 1991). There are two isoforms of TrkA, which differ by six additional amino acids near the extracellular transmembrane domain of one variant (TrkA<sub>II</sub>) (Clary and Reichardt, 1994). The p75 receptor is a transmembrane glycoprotein, which binds all neurotrophins with equal affinity. Actions by p75 receptor are classed into two categories. First, p75 is a Trk co-receptor that can increase or suppress neurotrophin-mediated Trk receptor activity. Second, p75 can activate signalling cascades that can induce apoptosis or promote neuron survival (Casaccia-Bonofil et al., 1999; Dobrowsky et al., 1994; Friedman and Greene, 1999; Roux and Barker, 2002). Although the signalling cascades triggered by the p75 receptor remain elusive, studies have shown activation of NF- $\kappa$ B, Akt, and JNK pathways by the p75 receptor (Roux and Barker 2002).

NGF signalling is broad based, and dynamically regulated with many intracellular signalling cascades that also converge with signalling from other molecules (Sofroniew et al., 2001). Most neurons depend on BDNF, NT-3 or NT4/5 for survival and maturation; sympathetic, nociceptive, and sensory neurons depend on NGF for survival during their development (Levi-Montalcini, 1987; Lindsay, 1996). Upon maturation these neurons lose their dependence on NGF for survival and utilize NGF to specify and maintain neuronal phenotypes (Lewin et al., 1992; Lewin, 1996; Lindsay, 1996).

The current prevalent theory for NGF signalling is that NGF bound to TrkA at the axon terminal is internalized into signalling endosomes. NGF remains bound to the phosphorylated TrkA in its membranes while retrogradely transported in the lumen to the cell body, where TrkA activates downstream signalling molecules (reviewed in Campenot and MacInnis, 2003). Other possible retrograde signalling mechanisms have also been suggested: 1) Retrograde transport of phosphorylated TrkA unbound to NGF. 2) Retrograde transport of signalling molecules downstream of phosphorylated TrkA. 3) Serial propagation of phosphorylation among downstream signalling molecules. 4) Serial propagation of ionic fluxes, such as changes in cytosolic  $Ca^{2+}$  (Campenot and MacInnis, 2003).

#### ***1.4.3 Glial-cell-line-derived neurotrophic factor (GDNF)***

GDNF belongs to a second family of neurotrophic factors known as GDNF family ligands (GFLs). Other members of the GFLs are neurturin (NRTN), artemin (ARTN), and persephin (PSPN) (Sariola and Saarma 2003). GFLs have been shown

to maintain several neuronal populations in the CNS such as: midbrain dopamine neurons (Lin et al., 1993) and motoneurons (Henderson et al., 1993). GFLs have also been shown to support the survival and differentiation of peripheral neurons including sympathetic, parasympathetic, enteric, and sensory neurons (reviewed in Sariola and Saarma 2003).

All GFLs signal through receptor tyrosine kinase RET, and the ligand-binding specificity is determined by GFR $\alpha$  proteins. GDNF, NRTN, ARTN, and PSPN specifically bind to GFR $\alpha$ 1, GFR $\alpha$ 2, GFR $\alpha$ 3, and GFR $\alpha$ 4 respectively (Airaksinen and Saarma, 2002). GDNF dimer complexes with GFR $\alpha$ 1 homodimers which brings two RET molecules together, activating transphosphorylation of specific tyrosine residues (Y905, Y1015, Y1062, and Y1096) (reviewed in Sariola and Saarma, 2003) in their domains (Airaksinen and Saarma, 2002). RET can subsequently activate several intracellular signalling cascades including the MAPK pathway (Kaplan and Miller, 2000; Fisher et al., 2001), the PI3K and PLC $\gamma$  pathways, as well as the Src-family kinases (Airaksinen and Saarma, 2002). However, studies have also demonstrated that GDNF can signal independently of RET in RET deficient cell lines and primary neurons (Poteryaev et al., 1999; Trupp et al., 1999). Surprisingly, the neurotrophic effect of GDNF in both *in vitro* and *in vivo* experiments, except for motoneurons, requires transforming growth factor- $\beta$  (TGF- $\beta$ ) (Peterziel et al., 2002). TGF- $\beta$  is involved in GFR $\alpha$ 1 membrane translocation, thus, regulates GDNF signalling (Peterziel et al., 2002). Interestingly, RET phosphorylation increases with postnatal age in sympathetic neurons (Sariola and Saarma, 2003), and NGF has been reported to promote phosphorylation of RET51 via an “inter-receptor-tyrosine-

kinase” signalling mechanism (Tsui-Pierchala et al., 2002). These studies demonstrate that growth factors and their receptors participate in cross-talk that guides development (Sariola and Saarma, 2003).

### **1.5 Phosphatidylinositol-3-kinase (PI3K)**

PI3K, one of the primary effectors of Trk activity by NGF, is crucial for survival of several types of neurons (Huang and Reichardt, 2001). PI3K is a heterodimer comprised of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit (Sofroniew et al., 2001). Activation of PI3K involves binding of the regulatory subunit to activated RTKs directly or via adaptors (Sofroniew et al., 2001). Binding of PI3K to the intracellular domain of RTKs triggers the recruitment of the 110-kDa catalytic subunit to the plasma membrane where it interacts with membrane phosphoinositides (Carter and Downes 1992; Soltoff et al., 1992).

Studies have shown that purified PI3K phosphorylates phosphoinositol (PI), phosphatidylinositol-4-monophosphate (PI-4-P), and phosphatidylinositol-4,5-bisphosphate (PI-4,5-P<sub>2</sub>), generating phosphatidylinositol-3-monophosphate (PI-3-P), phosphatidylinositol-3,4-bisphosphate (PI-3,4-P<sub>2</sub>), and phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-P<sub>3</sub>) respectively (Whitman et al., 1988; Auger et al., 1989; Carpenter et al., 1990). Protein kinase B (PKB), also known as Akt, then interacts with the generated PIP<sub>2</sub> or PIP<sub>3</sub> and with the 3-phosphoinositide-dependent kinase (PDK1). PDK1 possesses a pleckstrin homology (PH) domain that binds PIP<sub>2</sub> or PIP<sub>3</sub> which is necessary for PDK1 to activate Akt (Alessi et al., 1997a, b; Cohen et al.,

1997; Stephens et al., 1998; Stokoe et al., 1997). Akt/PKB is a primary downstream effector of PI3K. It phosphorylates and controls several proteins that are critical in modulating cell survival (reviewed in Datta et al., 1999; Yuan and Yankner 2000); although not all Akt substrates are involved in cell survival (Huang and Reichardt, 2001). Mechanisms by which PI3K could influence cell functions include: via production of phosphoinositides, via phosphorylation of proteins on serine or threonine through endogenous protein kinase activity, or by serving as an adaptor (Huang and Reichardt, 2001). Cellular functions that PI3K have been shown to be involved with are: inhibition of apoptosis, mitogenesis, vesicle trafficking/secretion, cytoskeleton function regulation, and neurite elongation (Huang and Reichardt, 2001).

Other downstream effectors of PI3K are 1) the Ras/Erk pathway, which is the primary mitogen-conducting pathway 2) the PKC/MEK/Erk pathway 3) the Rac/JNKK/JNK pathway, which contributes partially to the mitogen signal transduction but involved primarily with other cell functions such as stress reaction or cytoskeleton reorganization (review in Krasilnikov 2000).

## **1.6 Luteinizing hormone releasing hormone (LHRH)**

A major focus of this thesis is to examine the mechanism by which LHRH regulates  $\text{Ca}^{2+}$  channel regulation; therefore, its basic properties will be discussed.

### ***1.6.1 LHRH***

Gonadotropin-releasing hormone (GnRH) also known as LHRH is a primary initiator of the hormonal cascade in the reproductive system (King and Millar, 1980). Although hypothalamic LHRH was known to be distinct in structure with a central role in regulating luteinizing hormone (LH) and follicle stimulating hormone (FSH), it is now evident numerous forms exist in vertebrates (King and Millar, 1980).

Within the 23 forms of known LHRH, the most common form is chicken LHRH II, which was initially isolated from chicken brain (Miyamoto et al., 1984). Chicken LHRH II is entirely conserved from fish to human; therefore, may be the earliest evolved form with vital functions (Millar and King, 1987). In addition to their role as a stimulator of luteinizing hormone release, LHRH has numerous other functions in vertebrates (Millar, 2005). These include neuroendocrine, paracrine, autocrine, neuromodulatory, and neurotransmitter functions (Millar et al., 1987; Millar and King, 1987; Emons and Schally, 1994).

As already mentioned, LHRH triggers a late slow excitatory post-synaptic potential (late slow epsp) in BFG (Jan et al., 1979; Jan et al., 1980a; Jan et al., 1980b; Jan and Jan, 1982). Chicken II GnRH is approximately 100 times and 1000 times more potent than salmon GnRH and other naturally occurring GnRH analogs respectively, in BFG, which suggests that chicken II-GnRH (chicken II-LHRH) could be the endogenous transmitter that mediates the late slow epsp effect (Jones, 1987b). Features of LHRH receptors are characteristic of GPCRs such as an NH<sub>2</sub>-terminal followed by a seven alpha-helical transmembrane domain. Function of the extracellular loops of the seven transmembrane (7TM) domain typically involves

binding with agonists, whereas, the TM domains are involved with conformational changes following receptor activation. The intracellular domains of the receptor are associated G-protein and other molecules that are involved with intracellular signalling (Millar 2005). The major structural difference between mammalian and non-mammalian LHRH receptors is the presence of a carboxyl terminal in non-mammalian LHRH receptors and the absence of this terminal in mammalian LHRH receptors (Millar 2005). This difference may account for  $\beta$ -arrestin independency for internalization of mammalian LHRH receptors (Hislop et al., 2001).

LHRH increases IP<sub>3</sub> production and intracellular Ca<sup>2+</sup> level in BFGSG (Pfaffinger et al., 1988) and its effects are prevented by the PLC inhibitor U73122 (Ford et al., 2004). This suggests the involvement of PLC and the coupling of G $\alpha_{q/11}$  to LHRH-R. G $\alpha_{q/11}$  coupling to GnRH-R has been demonstrated in several systems (Hsieh and Martin, 1992; Stojilkovic and Catt, 1995; Naor et al., 1998). However, other studies have identified G $\alpha_{i/o}$  (Hawes et al., 1993; Imai et al., 1996) and G $\alpha_s$  (Hawes et al., 1993; Janovick and Conn, 1993; Kuphal et al., 1994) as the G-proteins mediating the effects of GnRH. A study by Elmslie and colleagues in 1990 showed that acute application of LHRH actually reduced Ca<sup>2+</sup> currents in a G-protein coupled manner (Elmslie et al., 1990), presumably via G $\alpha_{i/o}$ . Bley and Tsien in 1990 also showed that LHRH reduced Ca<sup>2+</sup> currents in a G-protein dependent manner as well as being PKC independent (Bley and Tsien, 1990).

GnRH activates Erk in various cells and cell lines (Mitchell et al., 1994; Sim et al., 1995; Roberson et al., 1995; Sundaresan et al., 1996; Reiss et al., 1997; Mulvaney et al., 1999; Han and Conn, 1999; Naor et al., 2000; Benard et al., 2001;



Klausen et al., 2002). Several lines of evidence have suggested that GnRH activates Erk through PKC and MEK dependent pathways with the possible contributions from tyrosine phosphorylation and Ca<sup>2+</sup> dependent mechanisms (Sundaresan et al., 1996; Reiss et al., 1997; Call and Wolfe, 1999; Mulvaney et al., 1999; Benard et al., 2001).

Currently, the two suggested pathways by which GnRH could activate Erk are: through activating the PKC-Raf-1 pathway; and through the growth factor transactivation by Src leading to Ras activation pathway (Benard et al., 2001; Klausen et al., 2002). GnRH activation of Erk via the PKC-Raf-1 pathway seems unlikely since B-Raf is the major Raf isoform in neurons and not Raf-1.

## **1.7 Signal transduction of G-protein coupled receptors**

Since one of the aims of this thesis is to examine actions mediated by GPCRs, their properties and mechanisms of action will be discussed.

### ***1.7.1 Properties of G-protein coupled receptors (GPCRs)***

Cellular signalling is achieved through many proteins, lipids, ions, peptides, and many other small molecules. Mechanisms by which GPCRs stimulate MAPKs fall into three general categories: activation of classical G-protein effectors such as PKA, PKC, and intracellular calcium; transactivation via classical receptor tyrosine kinases; and signals initiated by direct interaction between  $\beta$ -arrestins and molecules of the MAPK cascade (Luttrell, 2002).

Intracellular propagation of such events often requires that these signals be turned “on” and “off” in order to regulate the intensity and duration of the signals. G-proteins are one of the most ubiquitous of these intracellular switches that alternates between a guanosine triphosphate (GTP)-bound on state and a guanosine diphosphate (GDP)-bound off state. Heterotrimeric G-proteins (G-proteins) are consisted of  $G\alpha$ ,  $G\beta$  and  $G\gamma$  subunits in close proximity to the intracellular component of GPCRs. During the “off” state GDP-bound  $G\alpha$  subunits are tightly bound to their cognate  $G\beta\gamma$  heterodimer. This union assists  $G\alpha$  localization to the plasma membrane and is crucial for functional coupling to GPCRs. Upon GPCR activation GDP is released from the  $G\alpha$  subunit then GTP binds. The binding of GTP creates conformational changes in the flexible switch regions of  $G\alpha$ , resulting in the dissociation of  $G\beta\gamma$ . Free GTP-bound  $G\alpha$  and  $G\beta\gamma$  are then able to interact with downstream effector proteins. Hydrolysis of GTP to GDP by the intrinsic guanosine triphosphatase (GTPase) returns  $G\alpha$  to its inactive state. GDP-bound  $G\alpha$  re-associates with  $G\beta\gamma$  and terminates all interactions with effector proteins.

$G\alpha$  subunits are categorized into four primary classes based on preferential regulation of specific classes of effectors:  $G_{\alpha s}$ ,  $G_{\alpha i/o}$ ,  $G_{\alpha q/11}$ , and  $G_{\alpha 12/13}$ . All four classes of  $G\alpha$  subunits have well studied downstream effectors.  $G_{\alpha s}$  class typically activates adenylyl cyclase (AC). AC stimulation generates cAMP (Birnbaumer, 1992). cAMP is classically known to activate PKA, and it has also been shown to directly activate Ras (Ambrosini et al., 2000; Tsygankova et al., 2000) leading to Erk activation. Furthermore, cAMP can also activate Rap-1 (de Rooij et al., 1998; Kawasaki et al., 1998). However, direct activation of Rap-1 by PKA could also occur

(Vossler et al., 1997; Grewal et al., 2000). Activated Rap-1 then proceeds to activate Raf. Different isoforms of Raf exist in different types of cells, and in neurons B-Raf is predominant. Activation of B-Raf in neurons and PC-12 cells have been demonstrated to activate Erk (Erdhardt et al., 1995; Vossler et al., 1997; Dugan et al., 1999; Grewal et al., 1999; Grewal et al., 2000). Interestingly, in non-neuronal cells Raf-1 is present which is inhibited by the Rap-1-cAMP pathway, hence; Raf-1 activation inhibits ERK (Wu et al., 1993; Cook and McCormick, 1993; Hafner et al., 1994; D'Angelo et al., 1997; Dugan et al., 1999; Impey et al., 1999).

The second class of  $G_{\alpha}$ ,  $G_{\alpha i/o}$ , inhibits AC (Birnbaumer, 1992), as a result can inhibit Erk activation via the mechanism that is opposite of  $G_{\alpha s}$ . However,  $G_{\alpha o}$  has been shown to directly activate B-Raf causing Erk activation (Antonelli et al., 2000). In addition,  $G_{\alpha i/o}$  coupled receptor could interact with the  $G_{\beta\gamma}$  subunits leading to Erk activation (Pierce et al., 2001; Luttrell, 2002). The pathways that  $G_{\beta\gamma}$  subunits could follow to activate Erk include: transactivation of growth factor receptors (Daub et al., 1996; Ferguson, 2003); activation of Ras-GRF, a GEF that activates Ras (Crespo et al., 1994; Koch et al., 1994; Mattingly and Macara, 1996); activation of PI3K $\gamma$  (Hawes et al., 1996; Stephens et al., 1997) leading to PKC activation (Takeda et al., 1999) and subsequently, Erk activation.

The third class of  $G_{\alpha}$  subunit is the  $G_{\alpha q/11}$  class, which activates phosphoinositide-specific phospholipase C (PI-PLC). Upon activation, PI-PLCs will hydrolyze phosphatidylinositol 4, 5-bisphosphate (PIP<sub>2</sub>) generating inositol 1,4,5-triphosphate (IP<sub>3</sub>) and DAG second messengers (Voet and Voet, 1995). Generation of

IP<sub>3</sub> could elevate intracellular Ca<sup>2+</sup> levels by releasing intracellular Ca<sup>2+</sup> from IP<sub>3</sub>-sensitive Ca<sup>2+</sup> stores leading to ERK activation, as mentioned in a previous section.

The G<sub>α12/13</sub> class is capable of regulating the small G-protein RhoA family of effectors that have Dbl-homology (DH) and pleckstrin-homology (PH) domains (Worthylake et al., 2000). Although activation of Rho primarily affects cytoskeletal rearrangements, this pathway may contribute additional mechanisms to the activation of the Erk cascade through Rho-dependent PTKs (Naor et al., 2000). G<sub>α12/13</sub> can potentially induce JNK activation in many cellular contexts (Radhika and Dhanasekaran, 2001) via small GTPases Ras, Rac, Rho, and CDC42 (Goldsmith and Dhanasekaran, 2007). In certain cell types G<sub>α12/13</sub> can weakly stimulate Erk1/2 activation in a Ras-dependent manner (Mitsui et al., 1997), whereas in other systems they reduce Erk1/2 activation at the MEKs level (Voyno-Yasenetskaya et al., 1996). In certain cell types G<sub>α12</sub> has been shown to inhibit p38 MAPK (Dermott et al., 2004), but G<sub>α13</sub> stimulates p38 MAPK (Marinissen et al., 2003). In addition, agonists that stimulate G<sub>α12/13</sub>-coupled pathways remain unclear (Sugden and Clerk, 1997) although some studies suggest that thrombin and thromboxane A<sub>2</sub> signal through G<sub>α12/13</sub> in platelets and astrocytoma cells (Offermanns et al., 1994; Aragay et al., 1995).

Currently, there are five known human Gβ and twelve human Gγ subunit genes allowing for many potential combinations of Gβγ dimers. It was previously thought that the roles of Gβγ were to support coupling of Gαβγ to GPCRs and to act as Gα inhibitor with its guanine nucleotide dissociation inhibitor (GDI) activity. It is now recognized that free Gβγ after dissociating from Gαβγ can activate many of its

own effectors (McCudden et al., 2005). It is also known that free G $\beta\gamma$  is capable of regulating small G proteins and kinases. Activation of various GPCRs results in G $\beta\gamma$  mediated activation of MAPKs. Furthermore, it has been demonstrated that G $\beta\gamma$  can regulate certain AC forms, activate PLC- $\beta$  and PLC- $\epsilon$ , and localize GRK2 and GRK3 to the plasma membrane (Gao and Gilman, 1991; Tang and Gilman, 1991; Boyer et al, 1992; Taussig et al., 1994; Wing et al., 2001). However, the mechanisms that G $\beta\gamma$  interacts with its downstream effectors remain unclear.

Extended application of agonist to GPCRs often results in rapid receptor desensitization. There are two types of desensitization: 1) heterologous desensitization and 2) homologous desensitization. Heterologous desensitization of GPCRs involves phosphorylation of the receptor by PKA and PKC (Benovic et al., 1985; Pitcher et al., 1992). This form of desensitization is non-specific and occurs when any signal activates intracellular kinases, resulting in feedback from second messenger activated kinases impairing receptor activity and inhibiting production of second messengers. The mechanism involves these kinases phosphorylating serine residues on the C-terminus tail of the GPCR causing the receptor to uncouple from the G-proteins. The second form receptor desensitization termed homologous desensitization is more common to agonist-triggered GPCR desensitization. This process involves uncoupling the G-protein from the receptor, and also receptor internalization (Freedman and Lefkowitz, 1996). The mechanism includes several events: phosphorylation of the agonist-bound receptor by G-protein receptor kinases (GRKs), increasing receptor binding to the arrestin family of proteins, thereby

decreasing receptor availability for G-protein coupling (Tilakaratne and Sexton, 2005).

GRKs are comprised of a family of seven serine/threonine protein kinases (Kohout and Lefkowitz, 2003). Five members of the GRKs (GRK1, GRK4, GRK5, GRK6, and GRK7) are constitutively associated with the plasma membrane (Kohout and Lefkowitz, 2003). The other two members (GRK2 and GRK3) are recruited to the membrane after GPCR activation (Kohout and Lefkowitz, 2003). After an agonist binds, GPCR changes conformations which then promote binding of one or more GRKs. GRKs then phosphorylate GPCRs at specific residues within either the third intracellular loop or the carboxyl terminal domains (Ferguson, 2001). GRK phosphorylation of GPCR increases binding affinity of arrestin proteins which inhibit G-protein coupling (Lohse et al., 1990; Lohse et al., 1992). In turn, GRK phosphorylation of GPCR can be positively or negatively modulated by phosphorylation of second messenger kinases (Kohout and Lefkowitz, 2003).

Currently, there are four known arrestin proteins categorized into two groups based on sequence homology and their associated receptors and anatomical allocation (Ferguson, 2001). Members of the first group of arrestins are visual arrestin and cone arrestin (Shinohara et al., 1987; Yamaki et al., 1987; Murakami et al., 1993; Craft et al., 1994). Members of the second group of arrestins are  $\beta$ -arrestins ( $\beta$ -arrestin 1 and  $\beta$ -arrestin 2) (Lohse et al., 1990a; Attramadal et al., 1992).  $\beta$ -arrestins are ubiquitously distributed with predominance in neuronal tissues and spleen (Attramadal et al., 1992). The mechanisms by which arrestins promote GPCR desensitization includes physical uncoupling of GPCRs from heterotrimeric G-

proteins as well as targeting desensitized GPCRs to endocytosis (Ferguson, 2001). Targeting GPCRs to endocytosis is achieved by linking the receptors to clathrin and AP2 forming clathrin coated pits which will subsequently be internalized (Goodman et al., 1996; Laporte et al., 2000). This process results in reduction of the number of cell surface membrane-bound receptors (Tilakaratne and Sexton, 2005).

### ***1.7.2 Phospholipase C (PLC)***

Phospholipase C (PLC), which is categorized into four classes: PLC $\beta$  (1-4), PLC $\gamma$  (1-2), PLC $\delta$ , and PLC $\epsilon$  (Fukami, 2002) is the primary downstream effector of G $_{q/11}$ . PLC $\beta$  may be activated by the  $\beta\gamma$  subunits associated with G $_{q/11}$  or G $_{i/o}$  proteins as well as by G $_{q/11}$   $\alpha$ -subunits (Fukami, 2002). PLC $\gamma$  may be activated by receptor tyrosine kinases and also by non receptor tyrosine kinases (Fukami, 2002). PLC $\delta$  are controlled by Ca $^{2+}$  and PLC $\epsilon$  are controlled by Ras proteins (Fukami, 2002).

Activated PLC typically hydrolyzes PIP $_2$  to diacylglycerol (DAG) and inositol-1, 4, 5 - triphosphate (IP $_3$ ). The generated IP $_3$  could lead to elevation of intracellular Ca $^{2+}$  by releasing it from IP $_3$ -sensitive Ca $^{2+}$  stores (Rhee and Choi, 1992). Increased Ca $^{2+}$  levels can trigger CAM Kinase II-induced inhibition of Ras-GAP, thereby indirectly increasing Ras activation and subsequent ERK activation (Chen et al., 1998).

Elevated Ca $^{2+}$  levels may activate various Ras-GEF causing Ras activation (Farnsworth et al., 1995). Moreover, Ca $^{2+}$  can trigger protein tyrosine (PyK2) autophosphorylation leading to recruitment of nonreceptor kinase c-Src and activation of Erk in a Ras-dependent manner (Lev et al., 1995; Dikic et al., 1996; Della Rocca et

al., 1999). Production of DAG can activate PKC leading to a PKC $\alpha$ -Raf pathway activation of Erk, which is independent of Ras proteins (Kolch et al., 1993).

### ***1.7.3 Protein kinase C (PKC)***

Of mammalian PKC, there are 10 isoforms derived from 9 genes (Ohno and Nishizuka, 2002). These define a serine/threonine family of phosphorylating enzymes (Amadio et al., 2006). PKCs are ubiquitously expressed and influence multiple cellular functions (Amadio et al., 2006). PKCs mediate signals involved in acute processes (ion fluxes and neurotransmitter release), mid-term processes (receptor modulation), and also long-term processes (cell proliferation, synaptic remodelling, and gene expression) (Amadio et al., 2006).

All PKC isoforms have a highly conserved catalytic domain with a highly variable regulatory domain (Popp et al., 2006). Majority of the differences seen in sequence homology, substrate preferences and activators are accounted for by the differences in the regulatory domains (Ohno and Nishizuka, 2002; Newton, 2001). The different isoforms are grouped into three classes: 1) Classical PKC isoforms ( $\alpha$ ,  $\beta$ I,  $\beta$ II, and  $\gamma$ ) have a C1 domain containing a repeat of cysteine-rich motifs that form binding sites for phorbol esters and DAG and a Ca<sup>2+</sup>-dependent, phospholipids binding C2 domain (Popp et al., 2006). 2) Novel PKC isoforms ( $\delta$ ,  $\epsilon$ ,  $\eta$ , and  $\theta$ ) possess a C1 domain, a C2 domain that lacks amino acid residues necessary for Ca<sup>2+</sup> binding. Hence, activation of these isoforms is influenced by DAG and phorbol esters without requiring Ca<sup>2+</sup> (Popp et al., 2006). 3) Atypical PKC isoforms ( $\zeta$  and  $\lambda$ ) contain only a single cysteine-rich motif and no C2 domain; therefore, activation is



unaffected by DAG, phorbol esters, or  $\text{Ca}^{2+}$  (Popp et al., 2006). The precise mechanism of action of atypical PKCs remains unclear.

Phosphorylation of several serine/threonine sites in PKC is essential for the full activation of the enzyme in response to different stimulations (Hofmann, 1997; Parekh et al., 2000; Newton, 2003). The three important phosphorylation sites in cPKC and nPKC are: the activation loop site, the turn motif site, and the hydrophobic motif site, with the threonine residue in the activation loop being the most crucial phosphorylation site for PKC kinase activity (Cazaubon et al., 1994; Orr and Newton, 1994; Cenni et al., 2002; Liu et al., 2002).

Interaction with specific activators such as: physiological activator DAG or the analogue phorbol ester (PMA), allows the activation of the enzyme by opening its folded conformation (Amadio et al., 2006). This activation mechanism is related to the translocation of PKCs to different intracellular sites/membranes (Amadio et al., 2006). PKC are known to phosphorylate numerous intracellular proteins and many studies have also reported their involvement in mediating the effects of GnRH (Sundaresan et al., 1996; Bernard et al., 2001; Shah et al., 2003).

#### ***1.7.4 Protein kinase A (PKA)***

cAMP-dependent protein kinase (PKA) is a well characterized member of the protein kinase superfamily. Structurally, PKA is comprised of an inactive holoenzyme with two fully phosphorylated and an active catalytic subunits embedded within complexing with a dimer of regulatory subunits (Kim et al., 2006).

Activation of cAMP signalling entails binding of an extracellular ligand to a GPCR

and via G-proteins regulates one of many isoforms of adenylyl cyclase which generates cAMP (Tasken and Aandahl, 2004). Although other effectors of cAMP have been reported, the most demonstrated downstream effector system is PKA (Tasken and Aandahl, 2004).

The cAMP-PKA pathway has been implicated in regulating diverse cellular processes such as cell cycle, proliferation, and differentiation, regulation of chromatin condensation/ decondensation, nuclear assembly/disassembly, microtubule dynamics, as well as intracellular transport mechanism and ion fluxes (Tasken and Aandahl, 2004). Upon binding of cAMP to the regulatory unit, the active enzyme is released (Taylor et al., 2005). PKA has been reported to inhibit as well as activate ERKs in various systems (Stork and Schmitt, 2002): 1) PKA can impede Ras-dependent activation of Erks by inhibiting Raf-1 activation (Cook and McCormick, 1993). 2) PKA phosphorylation seems to block Raf-1 activity directly (Mischak et al., 1996). 3) Src can mediate PKA activation of Rap-1 in the activation of Erks (Stork and Schmitt, 2002). 4) In selected neurons, cAMP and PKA can activate Erk via Ras (Ambrosini et al., 2000; Iida et al., 2001).

### ***1.7.5 Mitogen-activated protein kinases (MAPK)***

Mitogen-activated protein kinases (MAPK) are a family of serine/threonine protein kinases that transduce extracellular stimuli into intracellular post-translational and transcriptional responses (Seger and Krebs, 1995; Lewis et al., 1998; Widman et al., 1999). In mammalian cells, three MAPK families have been clearly characterized: Erk, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38

kinase (p38) (fig. 1) (Ma and Quirion, 2002). MAPK pathways relay, amplify and integrate extracellular signals from a broad range of stimuli and elicit an appropriate physiological response including cellular proliferation, differentiation, development, inflammatory responses and apoptosis (Zhang and Liu, 2002).

Mitogens, growth factors, and cytokines are known activators of Erk. The Erk subfamily includes Erk1/ Erk2/ Erk3. The biological responses commonly attributed to Erk are cell growth, differentiation, and development (Zhang and Liu, 2002).

Although most protein kinases require serine, threonine, or tyrosine residue phosphorylation, Erk activation requires an unusual dual- phosphorylation of serine and threonine residues. This phenomenon could be important in preventing non-specific activation of Erks, which may be potentially oncogenic (Sugden and Clerk, 1997).

The JNK/SAPK subfamily of MAPK has three isoforms (JNK1, 2, and 3). JNK1 and JNK2 are ubiquitously expressed while JNK3 is mainly expressed in neuronal and heart tissues (Nishina et al., 2004). Known activators of JNK include many types of stress such as UV and  $\gamma$ -radiation, inflammatory cytokines, and growth factors (Nishina et al., 2004). JNK activation can lead diverse biological responses such as inflammation, differentiation, growth, and apoptosis (Liu and Lin, 2005).

The p38 MAPK subfamily also responds to a wide range of extracellular stimuli, in particular, to stress factors such as UV radiation, hypoxia, osmotic shock, pro-inflammatory cytokines, and less often growth factors (Raman et al., 2007). Currently, at least four isoforms of p38 are known p38 $\alpha$ , p38 $\beta$ , p38 $\gamma$ , and p38 $\delta$  (Liu and Lin, 2005). Activation of p38 can lead to inflammation, growth, differentiation, and apoptosis (Zhang and Liu, 2002).

### ***1.7.6 Extracellular-regulated kinase (Erk)***

Extracellular-regulated kinases 1, 2 (Erk1/2) signal transduction is complex, and is influenced by numerous pathways with immense cross-talk. However, it is also the complexity that allows for regulating subtle differences, fine-tuning, and amplification of signals varying with signals and cell type. The nature of this complexity also creates enormous possibilities for convergence and divergence of signals to and from the Ras-Raf-MEK-Erk pathway (Caunt et al., 2006). Specificity of signals is maintained, at least partially, by two basic mechanisms (Pouyssegur et al., 2002): 1) by scaffolding proteins that assemble specific kinases into a complex (Whitmarsh and Davis, 1998), and 2) by each MAPK members having specified docking sites that ensure correct binding and activation only by the specific kinase (Tanoue et al., 2000). Erk1/2 are distributed throughout the cell, and they are associated with plasma membrane receptors and transporters (Raman et al., 2007).

Various components within the Erk cascade have also been discovered in lipid rafts and caveolae (Furuchi and Anderson, 1998). The classic receptor mediated signalling pathway to Erk activation is via the small GTPase Ras. Small GTPases are low molecular weight (20-24 kDa) monomeric proteins with intrinsic GTP-hydrolysing activity (Bhattacharya et al., 2004). Small GTPases contribute to a wide range of functions such as: regulation of gene expression, cell proliferation, cell migration, cytoskeletal rearrangement, intracellular vesicle trafficking, and protein nucleocytoplasmic transportation (Tilakaratne and Sexton, 2005). Ras is a small monomeric GTP binding protein within a superfamily of over 150 members. The Ras superfamily has 6 subfamilies: Ras, Rho, Ran, Rab, Arf, and Kir/Rad/Rem (Ehrhardt et al., 2002). Within the Ras subfamily there are 13 members categorized into 5

groups: p<sup>21</sup>Ras (H-Ras, N-Ras, and K-Ras), R-Ras, M-Ras, Rap, and Ral (Ehrhardt et al., 2002). In order for Ras to be activated it must be translocated from the cytoplasm to the cell membrane where GTP/GDP exchange can take place. Ras is subsequently anchored to the plasma membrane through post-translational isoprenylation (farnesylation or geranylgeranylation), which targets proteins with a CaaX motif that is common in the Ras family members (Casey, 1995). The GTP/GDP exchange process is conducted by guanine-nucleotide exchange factors (GEFs), which target GDP-bound Ras then promote the exchange of GTP for GDP to activate Ras (Ehrhardt et al., 2002). GEF members that activate Ras are SOS1/2, Ras-GRF, Ras-GRP, and Epac 1/2 (Ehrhardt et al., 2002). GEFs are activated by various signals such as phosphorylation, diacylglycerol, Ca<sup>2+</sup>, and cyclic nucleotides (Ehrhardt et al., 2002). Inactivation of G-protein is achieved by GTPase activating proteins (GAPs), which increase G-proteins GTPase activity (Dovovan et al., 2002).

Once Ras is activated it recruits and activates the serine/threonine MAPK kinase kinase (Raf) at the plasma membrane. Currently, the three known members of the Raf family are: A-Raf, B-Raf, and Raf-1, with B-Raf as the primary isoform in neurons (Marais et al., 1997). Interestingly, Ras binding alone could activate B-Raf but not Raf-A or Raf-1 (Marais et al., 1997). Activated Raf could subsequently activate a threonine/tyrosine MAPK kinase (MEK) that in turn activates Erk (Malumbres and Pellicer, 1998). Activation of Erk by growth factors and other agonists triggers its translocation to the nucleus. This translocation gives Erk1/2 access to nuclear transcription factors and other nuclear proteins that are then phosphorylated or stabilized to give relevant changes in gene expression (Raman et al., 2007) such as cAMP response element-binding protein (CREB), Elk, Ets, Myc,


and p90-RSK (ribosomal S6 kinase) that participate in DNA transcription, cell growth, and cell division (Malumbres and Pellicer, 1998).

### **Statement of Problem**

Studies have shown that target-derived NGF is responsible for the maintenance of TTX-sensitive and TTX-insensitive  $I_{Na}$ , as well as N- and L-type calcium currents ( $I_{Ca,N}$  and  $I_{Ca,L}$ ) in adult BFG B-neurons (Lei et al., 1997; Lei et al., 1998; Lei et al., 2001; Petrov et al., 2001). The effects of NGF on  $I_{Ca}$  in serum-free, defined medium cultures are transduced via the MAPK pathway (Lei et al., 1998), whereas the transduction mechanism that is responsible for NGF-induced increase in  $I_{Na}$  remains to be determined. In addition, LHRH has been demonstrated to be capable of regulating functional expression of  $Ca^{2+}$  channels (Ford et al., 2003a).

The work in this thesis in conjunction with electrophysiological data (Ford dissertation, 2003) is undertaken to examine 1) whether LHRH-induced increase in  $I_{Ca}$  in BFG occurs via the MAPK pathway similar to NGF 2) how G-protein coupled receptors signal to the MAPK pathway 3) the mechanism by which NGF produces long-term increase in  $I_{Na}$  4) whether LHRH has access to the transduction mechanism by which it can produce long-term increase in  $I_{Na}$  in a similar manner as NGF.

# Mitogen activated protein kinases (MAPKs)



Modified from Cell Signaling Technology

**Figure 1. Schematic of mitogen activated protein kinases (MAPKs) cascade. A) Erk cascade B) p38 MAPK cascade C) SAPK/JNK cascade.**

**Chapter 2**  
**Methodology**



## **2.1 Methods**

### ***2.1.1 Cell culture***

The following procedures are adapted and modified from Selyanko et al., 1990 and Lei et al., 1997. Adult bullfrogs (*Rana Catesbeiana*) (size 10-15cm; body weight 250-350g) purchased from Wards Natural Sciences Ltd. were kept at room temperature. Dissection, isolation, dissociation, and culture procedures were conducted under aseptic conditions. Following pithing, the ventral section of each frog was sterilized with 9% iodine in ethanol. The abdominal muscle was removed to carefully expose the paravertebral sympathetic chain. The VIII<sup>th</sup>-X<sup>th</sup> paravertebral sympathetic ganglia were removed from both sides of each frog and dissociated with trypsin and collagenase (Selyanko et al., 1990). After enzymatic and mechanical dissociations, the dissociated neurons were resuspended in 3mL of defined, serum-free medium containing 73% Leibovitz's L-15 medium (Gibco) in HPLC grade water supplemented with 1mM CaCl<sub>2</sub>, 10mM glucose, 10 μM cytosine arabinoside, 100 μg/mL streptomycin and 100 units/mL penicillin at pH 7.2 (Lei et al., 1997). Neurons were plated into 24-well tissue culture plates at 1.2 ganglia/well, each well was then filled with 2mL of L-15 medium. The medium was exchanged the next day and every second day after that unless otherwise stated. Plates were maintained at room temperature (22°C) for 6-7 days.

### **2.1.2 Chemicals**

The following drugs and reagents were from Biomol (Plymouth Meeting, PA), wortmannin, PD98059 (2'-Amino-3'-methoxyflavone), perillic acid (PA),  $\alpha$ -Hydroxyfarnesylphosphonic acid ( $\alpha$ -HFA), H-89 (N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide-2HCl), Sp- and Rp-cAMPS (-Adenosine-3',5'-cyclic monophosphorothioate triethylamine salt), PMA (Phorbol 12-myristate-13-acetate) and 4 $\alpha$ -PMA . Chicken II Luteinizing Hormone Releasing Hormone (LHRH) and Nerve Growth Factor (NGF) were from Alomone Labs (Jerusalem, Israel). All other reagents were from Sigma-Aldrich (Oakville, Ont., Canada) or Fisher Scientific (Edmonton, AB, Canada). Some of the inhibitors used were exceedingly hydrophobic; therefore, were dissolved in dimethyl sulfoxide (DMSO) to make stock solutions. The stock solutions were then dissolved in culture media to obtain working concentrations. The final DMSO concentration in all cases was < 0.1%.

### **2.1.3 Morphology analysis**

Dissection, isolation, and dissociation were conducted following procedures described in *Tissue Culture* section. The dissociated cells were then redistributed into 2.5ml of medium in each of 20 35-mm polystyrene tissue culture dishes. Dishes were placed in a light proof, humidified chamber and maintained at room temperature (22°C) for 7 days. Dishes were divided into three groups: control, LHRH, and NGF. Control group dishes were maintained in L-15 medium, LHRH group received 100nM LHRH, and NGF group received 200ng/mL NGF. Drug treatments and

medium exchanges were performed the next day and every second day for 7 days. At day 7, pictures of cells from all three groups were captured at 100x magnification, counted, and grouped as having neurites or not having neurites.

#### ***2.1.4 Immunoblot analysis***

The VIII<sup>th</sup>, IX<sup>th</sup> and X<sup>th</sup> paravertebral ganglia were removed from both sides of 2 adult bullfrogs and the neurons dissociated with trypsin and collagenase as described above. The cell suspension was plated into 8 to 10-wells of a 24-well dish at a density of 1.2 ganglia/well. The dissociated cells were cultured in L-15 medium for 5-6 days. At day 6, some treatment groups were given L-15 supplemented with 50 $\mu$ M PD98059 for 24 hours to reduce basal phosphorylation of Erk. Incubation with 100nM LHRH began after two 5 min washes in L-15 to remove PD98059. Cells were incubated for 10 min, 1h, or 6h in the presence of the peptide. NGF experiments involved treatment of different groups of cells with 200ng/ml NGF for 15 min, 1h, 6h, and 6 days. BFGF neurons cultured in 24-well dishes were washed with ice cold L-15 medium prior to harvesting. Akt experiments included 4 treatment groups: 100nM LHRH treatment for 10 min; 200ng/ml NGF treatment for 15 min; 1 $\mu$ M wortmannin treatment for 6hrs; and 1 $\mu$ M wortmannin pre-treatment for 6hrs followed by 200ng/ml NGF incubation for 15 min. PKA experiments involved incubation with Sp-cAMP or its inactive form Rp-cAMP for 1hr to activate PKA then Erk phosphorylation was determined. PKC experiments involved incubation with PMA or its inactive form 4 $\alpha$  PMA for 1hr to activate PKC then Erk phosphorylation was determined. Procedures for harvesting neurons and electrophoresis were based on

modified method described in Song and Posse de Chaves 2003. These neurons were washed with ice cold washing buffer with 1mM Na<sub>2</sub>VO<sub>4</sub> and 1mM NaF to inhibit phosphatase activity. Cells from two wells of the same treatment were harvested with modified Laemmli sample buffer (40 mM Tris-HCl pH 6.8, 0.002% bromophenol blue, 10% glycerol, 1% sodium dodecyl sulfate (SDS) and 4% 2-mercaptoethanol) and boiled for 2 min. Proteins were separated by SDS-PAGE on 10% polyacrylamide containing 0.1% SDS. After electrophoresis, proteins were transferred to 'Immobilin' polyvinylidene difluoride (PVDF; Bio-RAD; Hercules, CA, USA) membranes overnight at 4°C in 25mM Tris (192 mM Glycine, 16% methanol buffer, 0.1% SDS, and pH 8.3). Membranes were blocked for 1h in 0.1% TTBS (Tris Buffered Saline with 0.1% Tween-20) with 5% non-fat milk at room temperature and incubated in the primary antibody overnight at 4°C. The primary antibodies used were: rabbit polyclonal anti-phospho TrkA (Tyr490) (1:1000), anti-phospho p42/44 MAPK (Thr202/Tyr204) (Erk 1/ 2) (1:1000), and anti-phospho Akt (S473) (1:1000) from Cell Signalling Technology (Beverly, MA, USA); anti-pan-Trk polyclonal antibody Trk (C-14) (1:500), and polyclonal anti-Erk 1 (C-16) (1:1000) from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) monoclonal anti- $\alpha$ -tubulin (T9026) (1:2000) from Sigma, Canada and monoclonal anti- $\beta$ -tubulin (T4026) (1:800) from Sigma, Canada. Membranes underwent three washes in TBS, TTBS, and TBS followed by incubation with the secondary antibody (goat anti rabbit I<sub>Gg</sub>; Pierce, Brockville, Ont., Canada) (1:2000) in blocking buffer for 1 hr at room temperature. Immunoreactivity was detected using enhanced chemiluminescence ('ECL Plus Detection System' Amersham Biosciences, Piscataway, NJ, USA). Equal protein

loading was checked by probing for the non-phosphorylated forms of Erk 1/2, TrkA, or  $\alpha/\beta$ -tubulin.

To demonstrate that PKC is activated and not downregulated, cells were treated with PMA or 4 $\alpha$ PMA for 1hr each day for 6days. After treatments, cells were rinsed with ice cold phosphate buffered saline (with protease inhibitor cocktail, NaF, and Na<sub>2</sub>VO<sub>4</sub>) and then quickly transferred to homogenization buffer (250 mM sucrose, 2mM EGTA, 1mM EDTA, 20mM Hepes, 100mM NaF, 2mM Na<sub>2</sub>VO<sub>4</sub>, and protease inhibitor cocktail). Cells were lysed by sonication (3x5 sec) followed by protein assay determination to assess, normalize and load equal amount of protein for ultracentrifugation for 1hr at 100000 rpm at 4°C. The supernatants were saved as the soluble fraction, pellets fractions were rinsed twice with ice cold PBS then resuspended in homogenization buffer with 1% Triton X-100. Electrophoresis is performed on 10% SDS-PAGE followed by transfer to PDVF membrane for immunoblotting with antibodies that recognize total PKC $\alpha$ , PKC $\beta$ 1, PKC $\gamma$ , PKC $\delta$ , PKC $\epsilon$ , PKC $\xi$  (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). Bands were detected by enhanced chemiluminescence.

### ***2.1.5 Ras activation assay***

Ras activation experiments were adapted and modified using method described in Herrmann et al 1995. Cell culture density was increased in these experiments to 4 ganglia/well. After treatments, cells were rinsed with ice cold phosphate buffered saline [with protease inhibitor cocktail (Roche Diagnostic #11836153001), NaF, and Na<sub>2</sub>VO<sub>4</sub>] then immediately harvested and lysed in 300 $\mu$ L

of BOS buffer (50mM Tris-HCl, pH 7.4, 200 mM NaCl, 1% Nonidet P-40, 10% glycerol, 10 mM NaF, 2.5 mM MgCl<sub>2</sub>, 1 mM EDTA). A sample from each group was reserved for protein assay. Protein assay was performed on the lysates and protein concentration was normalized. Equal amounts of GST-RBD (gift of Dr. Jim Stone, Dept Biochemistry, University of Alberta) construct pre-coupled to glutathione-agarose beads in BOS buffer was added to each concentration normalized lysate group. Samples were incubated for 2hrs at 4°C with gentle shaking to capture activated Ras. Samples were then rinsed 3 times followed by addition of 2X sample buffer and boiling for 5 min to cleave glutathione-agarose beads from GST-RBD constructs with active Ras attached. Equal volumes of GST-RBD with bound active Ras in 2X sample buffer for each experimental group were loaded for gel electrophoresis. Anti-Ras antibody [from Upstate Upstate Cell Signaling Solutions/Millipore Corporation (Billerica, MA)] was used to detect active Ras across experimental groups and anti-GST antibody (from Abcam, Cambridge, MA) was used as loading control.

#### ***2.1.6 Rap-1 activation assay***

Procedures were followed according to EZ-Detect RAP-1 activation kit (Pierce Brockville, Ont., Canada). Cell culture density was increased to 4 ganglia/well. Briefly, after treatments, cells were rinsed with ice cold phosphate buffered saline (with protease inhibitor cocktail, NaF, and Na<sub>2</sub>VO<sub>4</sub>) then immediately harvested and lysed in 300uL of lysis buffer. A sample from each group is reserved

for protein assay. Protein assay was performed on the lysates and protein concentration was normalized. Equal amounts of GST-RalGDS-RBD construct were added to individual SwellGel<sup>R</sup> (immobilized glutathione disc) and each normalized lysate experimental group was immediately added to each individual SwellGel-GST-RalGDS-RBD construct. Samples were incubated for 1hr at 4°C with gentle shaking to capture activated Rap-1. Samples were then rinsed 3 times followed by addition of 2X sample buffer and boiling for 5 min to cleave glutathione beads from GST-RalGDS-RBD construct with active Rap-1 attached. Equal volumes of GST-RalGDS-RBD with bound active Rap-1 in 2X sample buffer for each experimental group were loaded for gel electrophoresis. Anti-Rap-1 antibody (from Pierce Brockville, Ont., Canada) was used to detect active Rap-1 across experimental groups and anti-GST antibody (from Abcam, Cambridge, MA) was as loading control.

## **2.2 Quantification**

Data from immunoblots were scanned and their densities were quantified using “Un-Scan-it gel” software (Silk Scientific, Orem, UT). Changes in density were assessed relative to loading controls from 3-4 gels for each experiment. For comparison and presentation of data from replicated experiments, relative densities were normalized to the control group in each particular series.

## **Chapter 3**

### **Results**



## 3.1 Results

### 3.1.1 Mechanism of LHRH-induced increase of $I_{Ca}$

It has been reported that  $I_{Ba}$  maximum current density in 6d cultured neurons was  $118 \pm 7$  pA/pF (fig 2A). This increased to  $158 \pm 16$  pA/pF ( $p < 0.02$ ) by 34% in cells cultured for 6d with  $0.45 \mu\text{M}$  LHRH (fig. 2B) (Ford dissertation, 2003). It has also been shown that this LHRH effect to increase  $I_{Ba}$  is not due to a change in the voltage-dependence of activation or inactivation (Ford et al., 2003a). This increase in  $I_{Ca,N}$  was shown to be a transcription-dependent event (Ford et al., 2003a). Hence, exposure to LHRH may induce synthesis or affect the trafficking of N-type  $\text{Ca}^{2+}$  channels. An LHRH-mediated change in  $I_{Ca}$  has been reported to involve MEK using the MEK inhibitor PD98059 ( $10 \mu\text{M}$ ) (Alessi et al., 1995). Moreover, this compound, which inhibits the NGF-induced increase in  $I_{Ba}$  in BFG neurons (Lei et al., 1998), also blocked LHRH-induced increase in current density (fig. 2C, 2D; Table 1) (Ford dissertation, 2003). These findings are consistent with the hypothesis that the effect of LHRH on the functional expression of  $\text{Ca}^{2+}$  channels involves the activation of MAPK via MEK.

If the effect of LHRH is mediated through the MAPK pathway, it should be possible to show the activation of MAPK after 6d exposure to LHRH. Examination of phosphorylation of Erk1/2 of the MAPK family was carried out by immunoblot analysis. All immunoblots figures represent results from at least three replicate experiments, except for figures 6 and 13 which had two replicate experiments. Immunoblot data are presented with representative blots such as figure 3A and as quantified and normalized to controls using the format shown in figure 3B. Although

prolonged exposure to 200ng/mL NGF induced an obvious increase in Erk 1/2 phosphorylation (fig. 3A, lane 2, summarized in fig. 3B), this was not observed in neurons exposed to 6d 100nM LHRH (fig. 3A, lane 3, summarized in fig. 3B). It has been suggested that Erk mediated cellular effects could depend strongly on the temporal pattern of Erk activation, such as, sustained activation of Erk is required for the induction of axonal growth (Huang and Reichardt, 2003). However, it is possible that LHRH may trigger a transient activation of Erk that may signal the surface expression of new Ca<sup>2+</sup> channels via a transcription-dependent manner (Ford et al., 2003a). As a result, a shorter 10min exposure to LHRH was conducted to test whether LHRH-induced transient activation of Erk. Because basal level of Erk phosphorylation was strong in untreated control neurons, this would intrude with Erk activation detection by short-term LHRH incubation. Therefore; it was necessary to pre-treat neurons with the MEK inhibitor, PD98059 (50μM for 24hrs) prior to LHRH exposure. Under these conditions, 100nM LHRH for 10min induced an obvious increase in Erk phosphorylation (fig. 4A, lane 3, summarized in fig. 4C).

Time course characterization of Erk phosphorylation revealed that maximal LHRH-induced Erk phosphorylation was obtained after 10min exposure, which then returned to basal activation levels after 6h of exposure to LHRH (fig. 4A, lane 5, summarized in fig. 4C). However, NGF induced sustained Erk activation throughout the duration of exposure (fig. 5A, lanes 2-4, summarized in fig. 5C). Anti-total Erk and anti-total TrkA were used as loading controls for the above experiments. No increase in Erk phosphorylation was detected when LHRH was applied in the continued exposure of PD98059 (fig. 6A, lane 4, summarized in fig. 6B).

At least two different small GTPases (Rap-1 and Ras) can contribute to the activation of MAPK by extracellular agonists (Sofroniew et al., 2001). Moreover, Rap-1 has been reported to participate in Ca<sup>2+</sup> channels regulation by neurotrophins in PC12 cells (Black et al., 2003). Therefore, Ras and Rap-1 pull down assays were performed to test their possible role in the action of LHRH. Figures 7A, lanes 3 and 4, and summary in figure 7B illustrate activation of Ras by both NGF and LHRH, but neither substance activated RAP-1 (fig. 7C, lanes 4 and 5, summarized in fig. 7D). Lane 1 in figures 7A and 7C are positive controls showing Ras and Rap-1 activation by GTP- $\gamma$ -S.

It is possible that the observed effect of LHRH was mediated by TrkA because Erk 1/2 is a well-defined downstream effector of TrkA, and since ligand binding to GPCR may lead to transactivation of Trk and other growth factors (Rajagopal et al., 2004). This seemed unlikely since LHRH did not trigger TrkA phosphorylation (fig. 4A, lanes 2 to 5, summarized in fig. 4B). On the other hand, 200ng/mL NGF induced clear TrkA phosphorylation (fig. 5A, lanes 2-4, summarized in fig. 5B). Furthermore, treatment with NGF but not with LHRH caused activation of the PI3K/Akt pathway, which is also downstream of TrkA (fig. 8A, lanes 2 and 3, summarized in fig. 8B).

Interestingly, in all of the immunoblot analyses performed both anti-phospho-Erk and anti-total Erk antibodies detected only a single band with molecular weight corresponding to Erk2, although the characteristic doublet was observed in rat neuronal samples performed in parallel (fig. 9, lanes 1 and 2). Since both anti-phospho-Erk and anti-total-Erk were unable to detect the band corresponding to Erk

1, it is likely that frogs do not express Erk1. However, another possibility is that mammalian-origin antibodies have limited cross-reactivity with frog proteins or that amphibian Erk1 has the same molecular weight as amphibian Erk2.

### ***3.1.2 How do LHRH receptors couple to MAPK?***

In pituitary cell lines, GnRH receptor signalling to MAPK has been reported to involve PLC and PKC (Reiss et al., 1997; Sim et al., 1995; Naor et al., 2000). Electrophysiological studies using the PKC inhibitor chelerythrin (Herbert et al., 1990) was used to investigate the role of PKC in LHRH-induced potentiation of  $I_{Ba}$  (Ford dissertation, 2004). The results suggest that chelerythrin (1  $\mu$ M) prevented LHRH-mediated increases in current density, as  $I_{Ba}$  recorded in the presence of chelerythrin plus LHRH was not significantly different from cells cultured for 6d with chelerythrin alone ( $P > 0.05$ ) (Table 1) (Ford dissertation, 2003). Antibodies directed against the phosphorylated forms of PKC $\beta$ II and PKC $\gamma$  were used to examine activation of PKC by LHRH. These antibodies revealed two bands corresponding to approximately 80 and 90-kDa isoforms and LHRH significantly increased the phosphorylation of phospho-PKC  $\beta$ II (fig. 10A, lane 2, summarized in fig. 10B). These results would be expected if LHRH signalling involves PKC. However, LHRH failed to significantly increase phosphorylation of PKC $\gamma$  (fig. 10A, lane 2, summarized in fig. 10C).

In certain pituitary cell lines, the actions of GnRH are mediated through PKA (Han and Conn, 1999). Moreover, signalling pathways involving PKA, and/or cAMP are known to affect the Ras-MAPK cascade (Naor et al., 2000; Impey et al., 1998).

These findings along with results from cells treated for 6d with H-89 (PKA inhibitor) (Chijiwa et al., 1990) plus LHRH did not show the increase in current density that was seen with LHRH alone ( $P < 0.05$ ) (table 1) (Ford dissertation, 2003). This finding suggests the possibility that PKA is also involved in the LHRH effect. However, the direct activation of PKA with the cAMP analogue Sp-cAMP was not sufficient to increase  $I_{Ba}$  density. Current densities recorded from cells treated with Sp-cAMP ( $57.3 \pm 4.2$  pA/pF) were no different than current density recorded from cells treated with the enantiomer Rp-cAMP, a competitive inhibitor of the activation of PKA by cAMP ( $63.8 \pm 2.8$  pA/pF) ( $p > 0.05$ ) (Ford dissertation, 2003). To demonstrate that the lack of electrophysiological effects of the extracellularly-applied Sp-cAMP were not due to penetration failure into the neurons, Erk activation in response to extracellular Sp-cAMP by immunoblotting was measured. The effects of Sp-cAMP were compared with the inactive isomer Rp-cAMP (fig. 11A, lanes 5 and 6, summarized in fig. 11B). The effects of 10 $\mu$ M (concentration used for electrophysiology studies) Sp-cAMP were weaker than that of 80nM (concentration used for electrophysiology studies) PMA (fig. 11A, lanes 5 and 3, summarized in fig. 11B) on ERK activation and 10 $\mu$ M (concentration used for electrophysiology studies) Rp-cAMP was ineffective. This confirms the effectiveness of extracellularly-applied Sp-cAMP. The requirement for PKA activation for the action of LHRH is illustrated further by experiments shown in figures 11C and 11D. This shows the possibility of the competitive cAMP antagonist, Rp-cAMP (80 $\mu$ M, concentration used for electrophysiology studies) attenuating LHRH activation of Erk. These results, taken together, with results from the inhibition of PKA and PKC during stimulation with

LHRH suggest that both pathways (PKA and PKC) are necessary in the regulation of  $\text{Ca}^{2+}$  channels by LHRH, yet only PKC on its own is sufficient to produce this effect. In other words, PKA may be “necessary but insufficient” to alter the functional expression of  $\text{Ca}^{2+}$  channels.

A concern with the use of phorbol ester is that prolonged exposure may downregulate rather than activate PKC. Therefore, intermittent application protocol was developed for electrophysiological experiments in hope of promoting sustained PKC activation for the 6d duration experiments (Ford dissertation, 2003). In these experiments BFG B-cells treated with the phorbol ester PMA at 80nM for 1hr/day over 6 days to activate PKC (Ryves et al., 1991) showed  $I_{\text{Ba}}$  densities ( $70.8 \pm 5.8$  pA/pF) (fig. 2F) that were significantly greater than neurons treated with 4 $\alpha$ PMA, the negative control for PMA ( $55.4 \pm 4.3$  pA/pF) (fig. 2E) ( $p < 0.05$ ). Figure 11A and its summarized data in figure 11B illustrate the effect of time course treatments with 80nM PMA. 10min and 1hr PMA exposure induced obvious phosphorylation of both approximately 80 and 90kDa isoforms of PKC $\beta$ II (lanes 3 and 4). By contrast, the continuous 24h exposure of 80nM PMA showed an attenuation of PKC $\beta$ II phosphorylation (fig. 11A and lane 5). However, intermittent application of 80nM PMA as was done for electrophysiological experiments (1hr/d for 6d) failed to convincingly demonstrate increase in PKC $\beta$ II phosphorylation (fig. 11A and lane 6). The intermittent PMA application protocol did not achieve the sustained PKC activation as previously anticipated. This may be of little consequence as the effect of LHRH on Erk phosphorylation is transient (fig. 4A, lanes 3 to 5, summarized in fig. 4C). Hence, the first hour exposure of PMA to neurons in the electrophysiological

experiments (Ford dissertation, 2003) and the transient activation of PKC $\beta$ II likely initiated the transcriptional changes responsible for altered functional expression of I<sub>Ca</sub>. Subsequent applications of PMA likely did not activate PKC but this is irrelevant if the first stimulus initiated the signal for altered channel expression.

### ***3.1.3 Mechanism of NGF-induced increase in I<sub>Na</sub>***

It has been shown that long-term exposure of 200ng/mL to BFGF B-neurons resulted in a doubling of Na<sup>+</sup> current density, and this effect is transcription-dependent and does not reflect changes in activation or inactivation (Lei et al., 2001). Although the PI3K inhibitor, wortmannin failed to prevent LHRH or NGF-induced increases in I<sub>Ba</sub> (Lei et al., 1998), it was highly effective in inhibiting NGF-induced increases in total I<sub>Na</sub> (Lu et al., Society for Neuroscience abstract, 2002). Exposure of NGF for 10 days increased peak I<sub>Na</sub> density from 299.1±36.2 to 447.2±52.5 pA/pF (p<0.03) (fig. 12A and 12B) (Ford dissertation 2003). By contrast, NGF failed to affect I<sub>Na</sub> density in the presence of 1μM wortmannin (peak I<sub>Na</sub> density in wortmannin 343.5±38.5, in wortmannin + NGF 343.7±49.2 pA/pF) (p>0.85) (Ford dissertation, 2003). The effect of NGF was also blocked by the more selective PI3K inhibitor, LY294002 (10μM). Peak I<sub>Na</sub> in LY294002 was 328.5±35.3 compared to 327.0±33.6 pA/pF (P<0.95) in the presence of LY294002 + NGF (Ford dissertation 2003). These findings along with immunoblot results indicating NGF's failure to activate Akt in the presence of wortmannin (fig. 13A, lanes 3 and 4, summarized in fig. 13B) suggest the involvement of the PI3K pathway in the action of NGF on Na<sup>+</sup> channel expression.

### ***3.1.4 Does LHRH activate Akt?***

Peak, total  $I_{Na}$  density is unaffected by LHRH. In 6d cultures, maximum  $I_{Na}$  was  $238.8 \pm 35.0$  pA/pF in  $0.45 \mu\text{M}$  LHRH compared with  $229.9 \pm 1.5$  pA/pF ( $p > 0.8$ ) for controls (Ford dissertation, 2003). Similarly, for 9d cultures in LHRH, current density in LHRH was  $276.1 \pm 41.5$  pA/pF, and  $260.0 \pm 35.3$  pA/pF ( $p > 0.75$ ) for controls (Lu et al., Society for Neuroscience abstract, 2002).

Since NGF is capable of exerting effects via both the MAPK and PI3K pathways (Kaplan and Stephens 1994; Sofroniew et al., 2001), the present data suggest that the PI3K pathway is involved in regulation of  $I_{Na}$  and previous data suggest the MAPK pathway is involved in NGF regulation of  $I_{Ca}$  (Lei et al., 1998). Since LHRH regulates  $\text{Ca}^{2+}$  channels but not  $\text{Na}^+$  channels, it may only be able to signal via the MAPK pathway and not through the PI3K pathway. Experiments were performed to examine the effect of LHRH on the phosphorylation of Akt, one of the downstream effectors of PI3K (Sofroniew et al., 2001). Figure 8A, lanes 2 and 3, summarized in figure 8B show that 10min exposure to 100nM LHRH failed to increase Akt phosphorylation, in contrast, a robust increase in Akt phosphorylation was seen after 15 min 200ng/mL NGF exposure. Furthermore, the effect of NGF was attenuated by 6hr pre-treatment to the PI3K inhibitor, wortmannin at  $1 \mu\text{M}$  (fig. 13A, lanes 2-4, summarized in fig. 13B).

### ***3.1.5 LHRH effect is independent of neurite outgrowth***

It is possible that effects on ion channels simply reflect an overall neurotrophic effect that is cells are healthier with trophic support. In order to



determine if LHRH and NGF effects are independent of neurite outgrowth, morphology of the neurons were examined. In these experiments 28 of 65 control cells (fig. 14A) had neurite outgrowth, 25 of 78 LHRH treated cells (fig. 14A) had neurite outgrowth, and 48 of 56 NGF treated cells (fig. 14A) had neurite outgrowth after 7 days in culture (fig. 14). The lack neurite outgrowth in LHRH treated cells (fig. 14C) when compared to control (fig. 14B) results along with transient effect on Erk activation by LHRH suggest that LHRH regulation of functional expression of  $\text{Ca}^{2+}$  channels is independent of neurite outgrowth. By contrast, NGF treated cells increased in number of cells sprouted (fig. 14D) along with sustained Erk activation as discussed earlier suggest that effects of NGF on  $\text{Na}^+$  and  $\text{Ca}^{2+}$  regulation may be contributed by neurite outgrowth.


**Table 1**

	<b>Control I<sub>Ba</sub> Density (pA/pF) Blank Control</b>	<b>I<sub>Ba</sub> Density in LHRH (pA/pF) Positive Control</b>	<b>I<sub>Ba</sub> Density in Inhibitor (pA/pF)</b>	<b>I<sub>Ba</sub> Density in LHRH + Inhibitor (pA/pF)</b>
<b>PD98059 (10μM)</b>	117.7±6.8 (49)	158.4±16.0 (35) <i>a</i>	112.1±9.9 (10)	129.3±9.1(20)
<b>Chelerythrine (1μM)</b>	117.7±6.8 (49)	175.4±16.0 (35) <i>a</i>	74.0±4.0 (28)	90.8±9.2 (25)
<b>U73122 (20μM)</b>	67.2±7.3 (23)*	116.8±16.4 (19)* <i>a</i>	63.4±4.7 (25)	67.3±5.3 (26)
<b>H-89 (1μM)</b>	117.7±6.8 (49)	175.4±16.0 (35) <i>a</i>	122.6±10.2 (21)	96.0±4.9 (27)
<b>Wortmannin (100nM)</b>	117.7±6.8 (49)	175.4±16.0 (35) <i>a</i>	48.3±6.2 (18)	72.1±8.4 (17) <i>b</i>

Modified from Ford Dissertation 2003

**Table 1** Data are expressed as means±SEM with n-values in parentheses; statistical tests done with one-way ANOVA. Current densities are maximum values recorded at 0mV. \*Control values for U73122 were obtained with the inactive analogue, U73343. *a* P<0.05 compared to 'blank' control; *b* P<0.05 compared to inhibitor alone. All other data for the blank and positive controls were pooled and obtained from cells in serum-free defined medium. Inhibitors: PD98059, inhibitor of MEK. Chelerythrine, inhibitor of PKC. U73122, inhibitor of PLC. H-89, inhibitor of PKA. PP1, inhibitor of Src kinases. Wortmannin, inhibitor of PI3 kinase.


Figure 2




Modified from Ford Dissertation 2003

**Figure 2. Long-term regulation of total  $I_{Ca}$  by LHRH and phorbol ester.** All recordings are families of  $I_{Ba}$  produced in response to 20mV incremental steps from a holding potential of -90mV. **A)** Currents recorded after 6d in defined-medium culture. **B)** Currents recorded after 6d in the presence of 0.45 $\mu$ M LHRH (note larger amplitude compared to **A**), lower trace is voltage recording from neuron illustrated in upper trace. **C)** Family of  $I_{Ba}$ 's recorded after 6d in the presence of the MEK inhibitor PD98059 (10 $\mu$ M). **D)** Currents recorded after 6d in the presence of 0.45 $\mu$ M LHRH plus PD98059 (note similarity in amplitude compared to **C**). **E)** Currents recorded after 6d in the presence of 4 $\alpha$  phorbol (80nM). **F)** Currents recorded following 1hr daily exposure to 80nM PMA for 6d (note increased amplitude compared to **E**). Calibration bar in **A** refers to all current traces.


**Figure 3**




**Figure 3. Activation of Erk by 6d exposure to NGF, and lack of Erk activation by 6d exposure to LHRH.** The figure shows representative blots as well as quantification of data from 3 replicate experiments. The symbols, (circles, diamonds or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in blot density relative to loading controls. For further ease of comparison these ratios were normalized to the ratio observed in the control experimental situation. **A)** Effect of long term (6 days) exposure to NGF (200ng/ml) or LHRH (100nM). **B)** Quantification of data from 3 experiments similar to that illustrated in **A**.




**Figure 4. Activation of Erk and lack of activation of TrkA by LHRH.** The symbols, (circles, diamonds or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Neurons were incubated without or with 50  $\mu$ M PD98059 for 24h. At the end of the incubation, cultures as indicated were given 100 nM LHRH for times as specified. **B) and C)** Quantification of data from 4 experiments similar to that illustrated in **A** to illustrate LHRH activation of Erk but not TrkA.



**Figure 5. Sustained activation of Erk and TrkA by NGF.** The symbols, (circles, diamonds or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Neurons were treated with or without 200ng/mL NGF for times as indicated. **B) and C)** Quantification of data from 4 experiments similar to that illustrated in **A** to illustrate NGF activation of Erk and TrkA.




**Figure 6. Lack of Erk activation by LHRH in the continued exposure to PD98059.** The symbols, (triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Untreated neurons, neurons treated with 100nM LHRH for 10 min, 50 $\mu$ M PD98059 24 hrs, or 50 $\mu$ M PD98059 plus 100nM LHRH for 24 hrs. **B)** Quantification of data from 2 experiments to illustrate the lack of Erk activation by LHRH in the continued exposure to PD98059.




**Figure 7. Activation of Ras but not Rap-1 by LHRH and NGF. A)** Neurons were cultured for 5-6 days then were treated with 100 nM LHRH for 10min, 200ng/mL NGF for 15min, 10 mM GTP $\gamma$ S for 30 min, or 100 nM GDP for 30 min. The symbols, (diamonds, circles or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. **B)** Quantification of data such as that shown in **A** for three replicate experiments. **C)** Neurons were subjected to the same treatments as in **A**, then cell lysates were added to GST-RalGDS-RBD Swellgel<sup>R</sup> to pull down activated Rap-1 and the supernatants were loaded and separated by SDS-PAGE. GST immunoreactivity was used as a loading control. **D)** Quantification of data such as that shown in **C** for three replicate experiments.



Figure 8




**Figure 8. NGF activation of Akt and TrkA and lack of effect of LHRH on Akt and TrkA activation.** The symbols, (circles or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Activation of Akt and TrkA by NGF and lack of effect of LHRH on Akt and TrkA activation. **B)** Quantification of data from 3 experiments similar to that illustrated in **A** to illustrate NGF activation of Akt and TrkA and lack of effect on Akt and TrkA by LHRH.




**Figure 9. Erk expression in rat and frog neurons.** Expression of Erk1 and Erk2 in rat superior cervical ganglia neurons (lane 1) versus expression of only Erk2 in BFSG neurons (lane 2).

Figure 10




**Figure 10. Activation of PKC $\beta$ II and not PKC $\gamma$  by LHRH and PMA.** The symbols, (circles, diamonds or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Immunoblots to illustrate activation of PKC $\beta$ II but not PKC $\gamma$  by LHRH and PMA, Note maximal activation of PKC $\beta$ II is seen after 1 h with PMA and activation is attenuated after 24 h exposure or during intermittent exposure as was done in electrophysiological experiments. **B) and C)** Quantitative representation of data from 3 replicate experiments similar to that presented in **A**.

Figure 11




**Figure 11. Activation of Erk by LHRH, PMA and Sp-cAMPS but not by Rp-cAMPS or 4 $\alpha$ -phorbol and Inhibition of LHRH – induced Erk activation by Rp-cAMPS.** The clear symbols, (circles, diamonds or triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Activation of Erk by LHRH, PMA and Sp-cAMPS but not by Rp-cAMPS or 4 $\alpha$ -phorbol. **C)** Inhibition of LHRH – induced Erk activation by Rp-cAMPS. **B) and D)** Quantitative representation of data from experiments similar to that presented in A and C.

Figure 12




Modified from Ford Dissertation 2003

**Figure 12. Long-term regulation of  $I_{Na}$  by NGF.** All recordings are families of  $I_{Na}$  produced in response to 10mV incremental steps from a holding potential of -85mV. **A)** Currents recorded after 10d in defined medium culture. **B)** Currents recorded after 10d in the presence of 200ng/ml NGF (note larger amplitude compared to **A**, lower trace is voltage recording from neuron illustrated in upper trace. Calibration bars in **B** refer to all current traces.



**Figure 13. NGF activation of Akt and attenuation of Akt activation by wortmannin.** The symbols, (triangles) indicate results from individual experiments. The black horizontal bars represent mean values for each experiment. All data were measured in terms of percentage change in gel density relative to loading controls. **A)** Phosphorylation level of Akt in untreated, NGF treated, wortmannin treated, NGF plus wortmannin treated neurons. **B)** Quantification of data illustrated in **A** from 2 replicate experiments illustrating the attenuation of NGF activation of Akt in the presence of wortmannin.

**Figure 14. A**



**Figure 14. B**






Figure 14. C





**Figure 14. D**



**Figure 14.** Cells from all three groups were capture captured at 100x magnification, counted, and grouped as having neurites or not having neurites. **A)** Representative picture of neurons in control group at day 7. **B)** Representative picture of neurons exposed continuously to 100nM LHRH at day 7. **C)** Representative picture of neurons exposed continuously to 200ng/mL NGF at day 7. **D)** Graph illustrating the percentage of neurons in each group having neurite outgrowth.

## **Chapter 4**

### **Discussion and Future Directions**

## 4.1 Discussion

All experiments in this thesis were performed on BFSG neurons following a pharmacological approach. This raises concerns about inhibitor concentration and specificity. Although molecular techniques such as RNA interference (Holen and Mobbs, 2004) or introduction of dominant negative or constitutively active Ras (Fitzgerald, 2000) may be considered, the lack of information regarding the bullfrog genome makes these approaches difficult. Since this study is a continuation of an extensive series of electrophysiological studies (Jassar et al., 1993; Lei et al., 1997; Lei et al., 1998; Lei et al., 2001; Petrov et al., 2001; Ford et al., 2003a) on BFSG neurons of *Rana Catesbeiana*, it is inappropriate to switch to a mammalian system which would make the molecular approaches more feasible (Black et al., 2003). However, as mentioned earlier, the BFSG system offers several important advantages as it has only two principal types of cells (B-neurons and C-neurons) that are easily identifiable on the basis on physical size and electrophysiological properties (Adams et al., 1986; Horn et al., 1988; Jassar et al., 1993; Smith, 1994; Ivanoff and Smith, 1995; Jobling and Horn, 1996; Thorne and Horn, 1997). Furthermore, adult BFSG neurons can be maintained in a serum-free, defined medium culture system for over 14 days (Lei et al., 1997). A serum-free, defined medium culturing system is free of complicating effects from exogenous neurotrophins that is critical for the study of trophic actions of neurotransmitters.

The main findings of this thesis confirm and extend electrophysiology findings from (Ford dissertation, 2003) and Lu et al., Society for Neuroscience 2002 abstract. They are 1) LHRH signals via the Ras-MAPK and not via Rap-1 pathway to

increase functional expression of N-type  $\text{Ca}^{2+}$  channel conductance in adult sympathetic neurons 2) LHRH signalling to Ras involves PKC $\beta$ II 3) PKA is necessary but not sufficient to affect the transduction process 4) NGF signals via the PI3K pathway to increase  $\text{Na}^+$  currents 5) LHRH fails to affect functional expression of  $\text{Na}^+$  channel current. It is therefore suggested that downstream signalling from LHRH has selective access to MAPK and not to PI3K.

#### ***4.1.1 Role of Ras-MAPK in the LHRH-induced increase in $I_{Ca}$***

Immunoblot analyses demonstrated that NGF phosphorylates and activates both Akt and Erk1/2 whereas; LHRH only induces phosphorylation of Erk1/2 and not Akt. These findings support the suggestion that the effect of LHRH is independent of the PI3K pathway (Koch et al., 1991; Lopez-Illasaca et al., 1997). The effect of LHRH may involve PLC and Ras-MAPK is supported by the lack of effect of PPI and wortmannin and positive results with the inhibitors U73122 and PD98059 (Ford dissertation, 2003) (Table 1). In addition, immunoblot data indicates that LHRH failed to activate TrkA which gives further evidence against a role for transactivation of growth factor receptors by LHRH. However, this mechanism of action has been reported in other GPCR systems (Rajagopal et al., 2004). Even though Rap-1 has been shown to be activated by surrogate growth factor receptors in PC12 cells (Black et al., 2003), this phenomenon does not seem to occur with native TrkA receptors in sympathetic neurons. This is supported by immunoblot experiments showing the ability of LHRH and NGF to activate Ras but not Rap-1, which also suggests that Ras is involved with gonadotropin effect on  $\text{Ca}^{2+}$  current (Fig. 7A, 7B, 7C, and 7D).

Classically, PKC activation is shown by monitoring the translocation of the protein from the cytosol to the membranes (reviewed in Woodgett and Hunter, 1987; Shirai and Saito, 2002). Although numerous attempts were carried out in hope demonstrating PKC translocation using an established protocol in other systems by performing ultra-centrifugation (100000 x g) to partition the cytosolic and membrane fractions, recoveries of both the membrane and cytosolic fractions were poor and inconsistent in our samples. With the availability of antibodies against phosphorylated forms of certain PKCs, they were chosen as an approach to demonstrate PKC activation. Some studies have reported the significance of PKC phosphorylation with respect to the activation of the proteins such as: purified PKC could be inactivated following phosphatase treatments (Pears et al., 1992); phosphorylation in the T500 site within the activation loop is essential for PKC $\beta$  activation (Orr and Newton, 1994); and removal of phosphate from the three catalytic domains is crucial to desensitization of conventional PKCs (Hansra et al., 1996).

The basis of all the LHRH experiments is the neurotrophic effects are mediated by a heterotrimeric G-protein. Other mechanisms such as: internalization of peptide-bound receptors to induce transduction processes (Miller and Lefkowitz, 2001); or a G-protein-independent receptor, such as tyrosine kinase, may have been involved. These possibilities seem unlikely as all reported effects of LHRH in neurons, endocrine glands and cancer cells seem to progress through heterotrimer G-proteins (Grundker et al., 2001; Kakar et al., 2002; McArdle et al., 2002; Cheng and Leung, 2000; Naor et al., 1998a; Naor et al., 2000). In addition, it is commonly

accepted that in gonadotrophs, LHRH triggers the Ras-MAPK via a GPCR; hence, it is reasonable to believe that a similar pathway exists in neurons.

LHRH receptors have been shown to be capable of activating different heterotrimeric G-protein and signalling pathways in different cell types (Conn et al., 1979; Kuphal et al., 1994). In mammalian cells and cell lines, GnRH receptors have been reported to couple to  $G_{q/11}$ ,  $G_s$ , and  $G_i$  (Hawes et al., 1993; Janovick and Conn, 1994; Stanislaus et al., 1997; Ulloa-Aguirre et al., 1998). Since LHRH activates PLC in BFSG neurons to increase  $IP_3$  production and  $Ca^{2+}$  concentration (Pfaffinger et al., 1988), as well as, suppressing M-type  $K^+$  current (Ford et al., 2003b; Ford et al., 2004), it is reasonable to suggest that BFSG LHRH receptors are also coupled to  $G_{q/11}$  proteins. Interestingly, a novel mammalian receptor has been reported for the type II GnRH (Millar et al., 2001), which may correspond with the BFSG receptor. It is unclear if this is the only receptor used by LHRH signalling in BFSG or if  $G_{q/11}$  is the principle and/or only  $G\alpha$  isoform used. However, a study by Boland and Bean reported that LHRH inhibited  $Ca^{2+}$  current in freshly dissociated BFSG neurons (Boland and Bean, 1993), which could imply that LHRH could act through  $G_{\alpha i}$  in BFSG neurons.

In certain pituitary cell lines, GnRH effect on Ras-MAPK is transduced through PKC (Sundaresan et al., 1996; Reiss et al., 1997). In addition, direct activation PKC with a phorbol ester has been shown to activate MAPK (Reiss et al., 1997). Electrophysiological findings with chelerythrine and U73122 indicate that LHRH receptor signals through PLC and PKC in BFSG B-cells (table 1) (Ford dissertation, 2003). As well, direct PMA stimulation of PKC is sufficient to increase

I<sub>Ba</sub> (Fig. 2G) (Ford dissertation, 2003), which suggests the possibility of PKC being both “necessary and sufficient” to regulate BFSG Ca<sup>2+</sup> channels. Furthermore, immunoblot studies using isoform specific antibodies suggest that PKCβII but not PKCγ is involved in the effect by LHRH. However, these studies do not exclude the possible role by other PKC isoforms. Since activation of PKC has been reported to influence inactivation of Na<sup>+</sup> conductances in various neuronal systems (Franceschetti et al., 2000), it is reasonable to predict that LHRH may have a similar effect in BFSG neurons. This was not observed (Ford dissertation, 2003).

Although landmark studies have shown cAMP inhibition of ERKs through PKA in a Ras-dependent manner (Burgering et al., 1993; Cooks and McCormick, 1993; Graves et al., 1993; Wu et al., 1993), other studies have reported cAMP requiring PKA and Ras to activate Erk in selected neurons (Ambrosini et al., 2000; Iida et al., 2001). In certain cell types, cAMP can inhibit cell proliferation, but in other cell types cAMP can stimulate cell proliferation and differentiation via Erk activation (Young et al., 1994; Vossler et al., 1997). Known studies of cAMP-mediated cell proliferation is triggered by GPCR that are G<sub>s</sub>-coupled (Stork and Schmitt, 2002). In PC12 cells the PACAP receptor, Pac1, is capable of inducing the cAMP/PKA pathway and the PLC pathway to activate Rap1 and Ras and synergistically activating Erk (Bouschet et al., 2003). Although Rap1 activation was shown to be essential for Erk activation, Rap1 activation on its own was not sufficient for efficient stimulation of Erk activity (Bouschet et al., 2003). Perhaps a similar mechanism could exist for the LHRH receptor in BFSG. This would explain the observation that H-89 attenuated the electrophysiological effects of LHRH, but Sp-

cAMP (a cAMP analogue) failed to mimic this action (Ford dissertation, 2003) even though it was capable of inducing a weak activation of Erk (fig. 11A, lane 5, summarized in fig. 11B). Hence, PKA may be “necessary but not sufficient” in mediating the effects of LHRH. Another example of permissive role of Ras is shown by a wild type Ras (p21<sup>Ras</sup>) study in PC12 cells that it is also “necessary but not sufficient” to mediate neurotrophin induction of Ca<sup>2+</sup> channels (Pollock and Rane, 1996).

NGF and LHRH both have effects on Ca<sup>2+</sup> channels; however, some differences do exist between their actions. The NGF effects as mentioned earlier involve an increase in I<sub>Ca,L</sub>, decreased inactivation of total I<sub>Ca</sub>, and an increase in I<sub>Ca,N</sub> (Lei et al., 1997). Whereas LHRH only increased I<sub>Ca,N</sub> but had no effect on activation or inactivation kinetics (Ford et al., 2003a). These findings may indicate that another pathway in addition to the Ras-MAPK pathway may be responsible for the I<sub>Ca,L</sub> and inactivation kinetics. Interestingly, the differences could perhaps relate to the transient Erk1/2 activation induced by LHRH (Fig. 4A, lanes 3 to 5, summarized in fig. 4C) compared to the ongoing activation triggered by NGF (fig. 5A, lanes 2 to 4, summarized in fig. 5C).

#### ***4.1.2 Role of PI3K in NGF-induced increase in I<sub>Na</sub>***

Electrophysiological data with LY294002 and wortmannin (Ford dissertation, 2003), and immunoblot experiments support the role of PI3K pathway in the action of NGF on Na<sup>+</sup> current. Since it has been reported that downstream signalling of PI3K often progresses via Akt (Sofroniew et al., 2001), NGF phosphorylation of Akt in our



BFSG system (fig. 8A, lane 3, summarized in fig. 8B) lends further support to the involvement of the PI3K in NGF-induced increase in  $I_{Na}$ .

Other studies have shown that in PC12 cells effects on  $Na^+$  density is Ras-independent (Fanger et al., 1993; Fanger et al., 1997; Hilborn et al., 1998); however, the study by Fanger and coworkers in 1997 suggested that members of the Src non-receptor tyrosine kinase may be involved instead of PI3K. One possibility for this discrepancy is that our studies were performed on native TrkA on intact adult neurons whereas Fanger and co-worker in 1997 performed their experiments on PC12 cells expressing surrogate platelet-derived growth factor (PDGF) beta receptors with mutations that eliminate activation of specific signalling molecules. Another possibility is that our pharmacological approach which is reliant on the supposed selectivity of the inhibitors may be less reliable than molecular techniques.

#### ***4.1.3 LHRH effect is independent of neurite outgrowth***

Erk mediated cellular effects are strongly dependent on the temporal pattern of Erk activation (Huang and Reichardt, 2003). Exposure of LHRH to BFSG neurons in our system resulted in transient activation of Erk (fig. 4A, lanes 3-5), whereas, exposure to NGF resulted in sustained Erk activation (fig. 5A, lanes 2-4).

Morphological analysis showed 7 days LHRH treatment did not increase neurite outgrowth as only 25 out of 78 cells had neurite outgrowth (fig. 14A, 14C) compared to control cells which had 28 of 65 control cells with neurite outgrowth (fig. 14A, 14B). By contrast, NGF treatment increased neurite outgrowth with 48 out of 56 cells having outgrowth (fig. 14A, 14D). These results are not surprising since

neurotrophins are classically known to be responsible for growth, development, and repair of the nervous system. Furthermore, Huang and Reichardt have suggested that sustained activation of Erk is required for induction of axonal growth (Huang and Reichardt, 2003).

#### ***4.1.4 Lack of effect of LHRH on Na<sup>+</sup> currents***

It appears that LHRH does not have an effect on I<sub>Na</sub> (Ford dissertation, 2003), which could be explained by its lack of effect on the PI3K pathway that is implicated in NGF-triggered increases in I<sub>Na</sub> (fig. 12A, and 12B). NGF appears to have access to both the PI3K pathway to regulate functional expression of Na<sup>+</sup> channels, and the Ras-MAPK pathway to regulate Ca<sup>2+</sup> currents. LHRH, on the other hand, appears to only have access to the Ras-MAPK pathway, can only regulates Ca<sup>2+</sup> currents.

As mentioned earlier, the physiological role of I<sub>M</sub> may be to act as a voltage-clamp for cells to resist depolarizing stimulus influence (Adams et al., 1982a); therefore, suppression of I<sub>M</sub> will give a powerful excitatory effect. Interestingly, LHRH has been shown to deplete PIP<sub>2</sub> causing M-channel suppression in BFSG neurons (Ford et al., 2003b; Ford et al., 2004) making the neurons more excitable. Since Ca<sup>2+</sup> channels play an important role in the generation of action potential in BFSG cells (Pennefather et al., 1985; Smith, 1994), and our results indicate LHRH increases functional expression Ca<sup>2+</sup> via the Ras-MAPK pathway suggest a pleiotropic effect of LHRH in BFSG neurons.

In BFSG neurons functional up-regulation of Na<sup>+</sup> and Ca<sup>2+</sup> channels by NGF is persistent provided that the target-derived neurotrophin is available. By contrast,

the neurotrophic effect by LHRH is more variable since its release is dependent on preganglionic nerve activity. These effects may be related to the transient effect of LHRH compared to the lasting effect of NGF on Erk1/2 phosphorylation. It has been shown that repetitive stimulation is more effective than burst stimulation at releasing LHRH in BFSG (Peng and Horn, 1991); therefore, LHRH regulation of  $\text{Ca}^{2+}$  channels may couple pre-ganglionic events to alterations in the electrical properties of post-ganglionic neurons. Since neurotransmitter release is dependent on  $\text{Ca}^{2+}$  influx, increased  $\text{Ca}^{2+}$  channel availability at sympathetic post-ganglionic terminals may govern sympathetic signals to target tissues. In comparison,  $\text{Na}^+$  channel regulation is dependent on the availability of target derived-NGF rather than ganglionic transmission. Hence, the differential regulation of channel types exists because of the ability of NGF to signal via both the MAPK and PI3K pathways compared to the selective activation of the Ras-MAPK pathway by LHRH (fig. 15). These results may provide a tool for the understanding of the cellular and biochemical mechanisms in disease states such as hypertension and congestive heart failure, by which sympathetic outflow to blood vessels, the heart, and other visceral organs is elevated.

#### **4.2 Future Directions**

The work performed in this thesis is a continuation of an extensive series of physiological studies (Jassar et al., 1993; Lei et al., 1997; Lei et al., 1998; Lei et al., 2001; Petrov et al., 2001; Ford et al., 2003a) on BFSG neurons of *Rana Catesbeiana*,

has provided biochemical verification for the differential regulation of Na<sup>+</sup> and Ca<sup>2+</sup> channels by NGF and LHRH. Although molecular approaches such as introduction of dominant negative form of Ras (Fitzgerald, 2000), or using RNA interference (Holen and Mobbs, 2004) would provide more definitive evidence for the involvement of the proteins in question, these techniques are currently only available for mammals and are not feasible due to the lack of information on the *Rana Catesbeiana* genome, as well as time consuming to develop the protocols. Furthermore, the neurons may not survive after being subjected to such manipulations for the 6d duration of our experiments. In our system the neurons survived nicely as demonstrated by the morphology data. Since electrophysiological evidence suggest the upregulation of Na<sup>+</sup> currents by NGF and Ca<sup>2+</sup> currents by NGF and LHRH, future experiments could be to investigate the expression of these channel proteins using pan-sodium channel and pan-calcium channel antibodies, which would provide direct evidence for channel upregulations. Even though the classical method of demonstrating PKC activation by looking at membrane translocation of PKC was unsuccessful, the phosphorylation of several serine/threonine sites in PKC has been shown to be essential for the full activation of the enzyme in response to different stimulations (Hofmann, 1997; Parekh et al., 2000; Newton, 2003). Our data suggest the involvement of PKC  $\beta$ II and not PKC $\gamma$ , but this does not exclude the possible role of other PKC isoforms, hence future studies could examine phosphorylation levels of other PKC isoforms. Moreover, immunoblot assays could be performed using Chelerythrine to inhibit PKC and determine Erk activation could also support the role of PKC in the effect by LHRH. A possible role of Akt in NGF upregulation of Na<sup>+</sup> current has been

implicated without definitive evidence. Future biochemical experiments could examine the expression of Na<sup>+</sup> channel proteins in the presence of an Akt inhibitor such as FPA-124 (available from Echelon Biosciences Inc., Utah, USA), would support the role of Akt in the effect by NGF.

Interestingly, a study by Chieffi and colleagues on frog *Rana esculenta* testes showed that there are variations through out a year in the expression of Erk proteins and their states of activation do not always correlate (Chieffi et al., 2000). Hence another future study could analyze the months by which the experiments were conducted to note the expression levels of Erk as well as the level of Erk activation observed to see if, perhaps, there is any trend or correlation in this regard.

Figure 15




Figure 15. Scheme to illustrate proposed mechanisms for NGF and LHRH regulation of Na<sup>+</sup> and Ca<sup>2+</sup> Channels.

## References

- Adams PR and Brown DA.** Synaptic inhibition of the M-current: slow excitatory post-synaptic potential mechanism in bullfrog sympathetic neurones. *J Physiol (Lond)* 332: 263-272, 1982.
- Adams PR, Brown DA, Constanti A.** M-currents and other potassium currents in bullfrog sympathetic neurones. *J Physiol (Lond)* 330: 537-572, 1982a.
- Adams PR, Brown DA, Constanti.** Pharmacological inhibition of the M-current. *J Physiol (Lond)* 332: 223-262, 1982b.
- Adams PR, Brown DA, Jones SW.** Substance P inhibits the M-current in bullfrog sympathetic neurones. *Br J Pharmacol* 79: 330-333, 1983.
- Adams PR, Constanti A, Brown DA, Clark RB.** Intracellular Ca<sup>2+</sup> activates a fast voltage-sensitive K<sup>+</sup> current in vertebrate sympathetic neurones. *Nature* 296: 749-749, 1982.
- Adams PR, Jones SW, Pennefather P, Brown DA, Koch C, Lancaster B.** Slow synaptic transmission in frog sympathetic ganglia. *J Expl Biol* 124: 259-285, 1986.
- Airaksinen MS and Saarma M.** The GDNF family: signalling, biological functions and therapeutic value. *Nat Rev Neurosci* 3: 383-394, 2002.
- Akasu T.** Adrenaline depolarization in paravertebral sympathetic neurones of bullfrogs. *Pflugers Arch* 411: 80-87, 1988.
- Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR.** PD098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. *J Biol Chem* 270: 27489-27494, 1995.
- Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M.** 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. *Curr Biol* 7: 776-789, 1997a.

**Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P.** Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B-alpha. *Curr Biol* 7: 261-269, 1997b.

**Amadio M, Battaini F, Pascale A.** The different facets of protein kinases C: old and new players in neuronal signal transduction pathways. *Pharmacol Res* 54: 317-325, 2006.

**Ambrosini A, Tininini S, Barassi A, Racagni G, Sturani E, Zippel R.** cAMP cascade leads to Ras activation in cortical neurons. *Brain Res Mol Brain Res* 75:54-60, 2000.

**Antonelli V, Bernasconi F, Wong YH, Vallar L.** Activation of B-Raf and regulation of the mitogen-activated protein kinase pathway by the G(o) alpha chain. *Mol Cell Biol* 11: 1129-1142, 2000.

**Aragay AM, Collins LR, Post GR, Watson AJ, Feramisco JR, Brown JH, Simon MI.** G12 requirement for thrombin-stimulated gene expression and DNA synthesis in 1321N1 astrocytoma cells. *J Biol Chem* 270:20073-20077, 1995.

**Arevalo JC and Wu SH.** Neurotrophin signaling: many exciting surprises! *Cell Mol Life Sci* 63: 1523-1537, 2006.

**Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG, Lefkowitz RJ.** Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. *J Biol Chem* 267: 17882-17890, 1992.

**Auger KR, Carpenter CL, Cantley LC, Varticovski L.** Phosphatidylinositol 3-kinase and its novel product, phosphatidylinositol 3-phosphate, are present in *Saccharomyces cerevisiae*. *J Biol Chem* 264: 20181-20184, 1989.

**Balkowiec A and David KM.** Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. *J Neurosci* 22 (23): 10399-407, 2002.

**Barrie AP, Clohessy AM, Buensuceso CS, Rogers MV, Allen JM.** Pituitary adenylyl cyclase-activating peptide stimulates extracellular signal-regulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells. *J Biol Chem* 272: 19666-19671, 1997.



**Benovic JL, Pike LJ, Cerione RA, Staniszewski C, Yoshimasa T, Codina J, Caron MG, Lefkowitz RJ.** Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. *J Biol Chem* 260: 7094-7101, 1985.

**Bernard O, Naor Z, Seger R.** Role of Dynamin, Src, and Ras in the Protein Kinase C-mediated activation of ERK by Gonadotropin-releasing Hormone. *J Biol Chem* 278: 4554-4563, 2001.

**Bhattacharya M, Babwah AV, Ferguson SS.** Small GTP-binding protein-coupled receptors. *Biochem Soc Trans* 32:1040-1044, 2004.

**Birnbaumer L.** Receptor-to-effector signaling through G proteins: roles for beta gamma dimers as well as alpha subunits. *Cell* 71:1062-1072, 1992.

**Black MJ, Woo Y and Rane SG.** Calcium channel upregulation in response to activation of neurotrophin and surrogate neurotrophin receptor tyrosine kinases. *J Neurosci Res* 74: 23-36, 2003.

**Bley KR and Tsien RW.** Inhibition of Ca<sup>2+</sup> and K<sup>+</sup> channels in sympathetic neurons by neuropeptides and other ganglionic transmitters. *Neurons* 4: 379-391, 1990.

**Blum R and Konnerth A.** Neurotrophin-Mediated Rapid Signaling in the Central Nervous System: Mechanisms and Functions. *Physiology* 20: 70-78, 2005.

**Boland LM and Bean BP.** Modulation of N-type calcium channels in bullfrog sympathetic neurons by luteinizing hormone-releasing hormone: kinetics and voltage dependence. *J Neurosci* 13: 516-533, 1993.

**Bosma MM and Hille B.** Protein kinase C is not necessary for peptide-induced suppression of M current or for desensitization of the peptide receptors. *Natl Acad Sci USA* 86: 2943-2947, 1989.

**Bothwell M.** Functional interactions of neurotrophins and neurotrophin receptors. *Annu Rev Neurosci* 18: 223-253, 1995.

**Bouschet T, Perez V, Fernandez C, Bockaert J, Eychene A and Journot L.** Stimulation of the ERK Pathway by GTP-loaded Rap1 Requires the Concomitant Activation of Ras, Protein Kinase C, and Protein Kinase A in Neuronal Cells. *J Biol Chem* 278: 4778-4785, 2003.

**Brown DA and Adams PR.** Muscarinic suppression of a novel voltage-sensitive K<sup>+</sup> current in a vertebrate neurone. *Nature (Lond)* 283:673-676, 1980.

**Burgering BM, Pronk GJ, van Weeren PC, Chardin P, Bos JL.** cAMP antagonizes p21ras-directed activation of extracellular signal-regulated kinase 2 and phosphorylation of mSos nucleotide exchange factor. *Embo J* 12: 4211-4220, 1993.

**Call GB and Wolfe MW.** Gonadotropin-releasing hormone activates the equine luteinizing hormone beta promoter through a protein kinase C/mitogen-activated protein kinase pathway. *Biol Reprod* 61: 715-723, 1999.

**Cameron HA, Hazel TG, McKay RD.** Regulation of neurogenesis by growth factors and neurotransmitters. *J Neurobiol* 36: 287-306, 1998.

**Campenot RB and MacInnis BL.** Retrograde Transport of Neurotrophins: Fact and Function. *J Neurobiol* 58: 217-229, 2004.

**Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC.** Purification and characterization of phosphoinositide-3-kinase from rat liver. *J Biol Chem* 265: 19704-19711, 1990.

**Carter AN and Downes CP.** Phosphatidylinositol 3-kinase is activated by nerve growth factor and epidermal growth factor in PC12 cells. *J Biol Chem* 267: 14563-14567, 1992.

**Casaccia-Bonnel P, Gu C, Chao MV.** Neurotrophins in cell survival/death decisions. *Adv Exp Med Biol* 468: 275-282, 1999.

**Casey PJ.** Protein lipidation in cell signaling. *Science* 268: 221-225.

**Catterall WA.** Structure and regulation of voltage-gated Ca<sup>2+</sup> channels. *Annu Rev Cell Dev Biol* 16: 521-555, 2006.

**Caunt CJ, Finch AR, Sedgley KR, McArdle CA.** GnRH receptor signalling to ERK: kinetics and compartmentalization. *Trends Endocrinol Metab* 17: 308-313, 2006.

**Cazaubon S, Bornancin F, Parker PJ.** Threonine-497 is a critical site for permissive activation of protein kinase C alpha. *Biochem J* 301: 443-448, 1994.

**Cenni V, Doppler H, Sonnenburg ED, Maraldi N, Newton AC, Toker A.** Regulation of novel protein kinase C epsilon by phosphorylation. *Biochem J* 363: 537-545, 2002.

**Chalazonitis A, Peterson ER and Crain SM.** Nerve growth factor regulates the action potential duration of mature sensory neurons. *Proc Natl Acad Sci USA* 84: 289-293, 1987.

**Chao MV.** Neurotrophin receptors: a window into neuronal differentiation. *Neuron* 9: 583-593, 1992.

**Chen Y, Cantrell AR, Messing RO, Scheuer T and Catterall WA.** Specific modulation of Na<sup>+</sup> channels in hippocampal neurons by protein kinase C epsilon. *J Neurosci* 25: 507-513, 2005.

**Chen HJ, Rojas-Soto M, Oguni A, Kennedy MB.** A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited by CaM kinase II. *Neuron* 20: 895-904, 1998.

**Cheng KW and Leung PC.** The expression, regulation and signal transduction pathways of the mammalian gonadotropin-releasing hormone receptor. *Can J Physiol Pharmacol* 78: 1029-1052, 2000.

**Chieffi P, Colucci-D'Amato GL, Staibano S, Franco R, Tramontano D.** Estradiol-induced mitogen-activated protein kinase (extracellular signal-regulated kinase 1 and 2) activity in the frog (*Rana esculenta*) testis. *J Endocrinol* 167: 77-84, 2000.

**Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T and Hidaka H.** Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-

isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. *J Biol Chem* 265: 5267-5272, 1990.

**Clary DO and Reichardt LF.** An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. *Proc Natl Acad Sci USA* 91: 11133-11137, 1994.

**Cohen P, Alessi DR, Cross DA.** PDK1, one of the missing links in insulin signal transduction? *FEBS Lett* 410: 3-10, 1997.

**Conn PM, Morrell DV, Dufau ML and Catt KJ.** Gonadotropin-releasing hormone action in cultured pituicytes: independence of luteinizing hormone release and adenosine 3', 5'- monophosphate production. *Endocrinology* 104: 448-453, 1979.

**Cook SJ and McCormick F.** Inhibition by cAMP of Ras-dependent activation of Raf. *Science* 262: 1069-1072, 1993.

**Craft CM, Whitmore DH, Wiechmann AF.** Cone arrestin identified by targeting expression of a functional family. *J Biol Chem* 269: 4613-4619, 1994.

**Craner MJ, Klein JP, Renganathan M, Black JA and Waxman SG.** Changes of sodium channel expression in experimental painful diabetic neuropathy. *Ann Neurol* 52: 786-792, 2002.

**Crespo P, Xu N, Simonds WF, Gutkind JS.** Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. *Nature* 369: 418-420, 1994.

**Cummins TR and Waxman SG.** Downregulation of tetrodotoxin resistant sodium currents and upregulation of rapidly repriming tetrodotoxin sensitive sodium current in small sensory neurons after nerve injury. *J Neurosci* 17: 3503-3514, 1997.

**D'Angelo G, Lee H, Weiner RI.** cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. *J Cell Biochem* 67: 353-366, 1997.

**Datta SR, Brunet A, Greenberg ME.** Cellular survival: a play in three Akts. *Genes Dev* 13: 231-241, 1999.

**Daub H, Weiss FU, Wallasch C, Ullrich A.** Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. *Nature* 379: 557-560, 1996.

**Della Rocca GJ, Maudsley S, Daaka Y, Lefkowitz RJ, Luttrell LM.** Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases. *J Biol Chem* 274: 13978-13984, 1999.

**Dermott JM, Ha JH, Lee CH, Dhanasekaran N.** Differential regulation of Jun N-terminal kinase and p38MAP kinase by Galpha12. *Oncogene* 23: 226-232, 2004.

**de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A and Bos JL.** Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* 396: 474-477, 1998.

**Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J.** A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. *Nature* 383: 547-550, 1996.

**Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA.** Activation of the sphingomyelin cycle through the low-affinity neurotrophin receptor. *Science* 265: 1596-1599, 1994.

**Dodd J and Horn JP.** A reclassification of B and C neurones in the ninth and tenth paravertebral sympathetic ganglia of the bullfrog. *J Physiol* 334: 255-269, 1983.

**Donovan S, Shannon KM, Bollag G.** GTPase activating proteins: critical regulators of intracellular signaling. *Biochim Biophys Acta* 1602: 23-45, 2002.

**Dugan LL, Kim JS, Zhang Y, Bart RD, Sun Y, Holtzman DM, Gutmann DH.** Differential effects of cAMP in neurons and astrocytes. Role of B-raf. *J Biol Chem* 274: 25842-25848, 1999.

**Edwards RH, Selby MJ, Rutter WJ.** Differential RNA splicing predicts two distinct nerve growth factor precursors. *Nature* 319: 784-787, 1986.

**Ehrhardt A, Ehrhardt GR, Guo X, Schrader JW.** Ras and relatives--job sharing and networking keep an old family together. *Exp Hematol* 30: 1089-1106, 2002.

**Elmslie KS, Zhou W, Jones SW.** LHRH and GTP-gamma-S modify calcium current activation in bullfrog sympathetic neurons. *Neuron* 5: 75-80, 1990.

**Emons G and Schally AV.** The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. *Hum Reprod* 15: 1364-1379, 2000.

**Erhardt P, Troppmair J, Rapp UR, Cooper GM.** Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells. *Mol Cell Biol* 15: 5524-5530, 1995.

**Fanger GR, Erhardt P, Cooper GM and Maue RA.** ras-independent induction of rat brain type II sodium channel expression in nerve growth factor-treated PC12 cells. *J Neurochem* 61: 1977-1980, 1993.

**Fanger GR, Vaillancourt RR, Heasley LE, Montmayeur JP, Johnson GL and Maue RA.** Analysis of mutant platelet-derived growth factor receptors expressed in PC12 cells identifies signals governing sodium channel induction during neuronal differentiation. *Mol Cell Biol* 17: 89-99, 1997.

**Farnsworth CL, Freshney NW, Rosen LB, Ghosh A, Greenberg ME, Feig LA.** Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF. *Nature* 376: 524-527, 1995.

**Ferguson SS.** Receptor tyrosine kinase transactivation: fine-tuning synaptic transmission. *Trends Neurosci* 26: 119-122, 2003.

**Fisher CE, Michael L, Barnett MW, Davies JA.** Erk MAP kinase regulates branching morphogenesis in the developing mouse kidney. *Development* 128: 4329-4338, 2001.

**Fitzgerald EM.** Regulation of voltage-dependent calcium channels in rat sensory neurones involves a ras-mitogen-activated protein kinase pathway. *J Physiol* 527 : 433-444, 2000.

**Fitzgerald EM and Dolphin AC.** Regulation of rat neuronal voltage-dependent calcium channels by endogenous p21-ras. *Eur J Neurosci* 9: 1252-1261, 1997.

**Ford CP.** Ion Channel Regulation By Neurotransmitters. Ph.D. Dissertation, 2003.

**Ford CP, Dryden WF and Smith PA.** Neurotrophic Regulation of Calcium Channels by the Peptide Neurotransmitter, Luteinizing Hormone Releasing Hormone. *J Neurosci* 23: 7169-7175, 2003a.

**Ford CP and Smith PA.** The Neuropeptide Transmitter LHRH Regulates Calcium Channels via the Ras-MAPK Pathway. *Soc Neurosci Abs* 26: 234.17, 2000.

**Ford CP, Stemkowski PL, Light PE and Smith PA.** Experiments to test the role of phosphatidylinositol 4, 5-bisphosphate in neurotransmitter-induced M-channel closure in bullfrog sympathetic neurons. *J Neurosci* 23: 4931-4941, 2003b.

**Ford CP, Stemkowski PL and Smith PA.** Possible role of phosphatidylinositol 4,5 bisphosphate in luteinizing hormone releasing hormone-mediated M-current inhibition in bullfrog sympathetic neurons. *Eur J Neurosci* 20: 2990-2998, 2004.

**Franceschetti S, Taverna S, Sancini G, Panzica F, Lombardi R and Avanzini G.** Protein kinase C-dependent modulation of Na<sup>+</sup> currents increases the excitability of rat neocortical pyramidal neurones. *J Physiol* 528 Pt 2: 291-304, 2000.

**Freedman NJ and Lefkowitz RJ.** Desensitization of G protein-coupled receptors. *Recent Prog Horm Res* 51:316-351, 1996.

**Friedman WJ and Greene LA.** Neurotrophin signaling via Trks and p75. *Exp Cell Res* 253: 131-142, 1999.

**Fukami K.** Structure, regulation, and function of phospholipase C isozymes. *J Biochem (Tokyo)* 131: 293-299, 2002.

**Furuchi T and Anderson RG.** Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). *J Biol Chem* 273: 21099-21104, 1998.

**Goh JW, Kelly ME, Pennefather PS.** Electrophysiological function of the delayed rectifier (IK) in bullfrog sympathetic ganglion neurones. *Pfluger Arch* 413: 482-486, 1989.

**Goh JW and Pennefather PS.** Pharmacological and physiological properties of the after-hyperpolarization current of bullfrog ganglion neurones. *J Physiol* 394: 315-330, 1987.

**Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, Kallen RG, Mandel G, Meisler MH, Netter YB, Noda M, Tamkun MM, Waxman SG, Wood JN and Catterall WA.** Nomenclature of voltage-gated sodium channels. *Neuron* 28: 365-368, 2000.

**Goldsmith ZG and Dhanasekaran DN.** G protein regulation of MAPK networks. *Oncogene* 26: 3122-3142, 2007.

**Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH, Benovic JL.** Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. *Nature* 383: 447-450, 1996.

**Gotz R, Koster R, Winkler C, Raulf F, Lottspeich F, Scharf M, Thoenen H.** Neurotrophin-6 is a new member of the nerve growth factor family. *Nature* 372: 266-269, 1994.

**Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG.** Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. *Proc Natl Acad Sci USA* 90: 10300-10304, 1993.

**Grewal SS, Horgan AM, York RD, Withers GS, Banker GA and Stork PJ.** Neuronal calcium activates a Rap1 and B-Raf signaling pathway via the cyclic adenosine monophosphate-dependent protein kinase. *J Biol Chem* 275: 3722-3728, 2000.

**Grewal SS, York RD, Stork PJ.** Extracellular-signal-regulated kinase signalling in neurons. *Curr Opin Neurobiol* 9: 544-553, 1999.



**Groul DL, Siggins GR, Pedjen A and Forman DS.** Explant of cultures of adult amphibian sympathetic ganglia: electrophysiological and pharmacological investigation of neurotransmitter and nucleotide action. *Brain Res* 223: 81-106, 1981.

**Grundker C, Volker P and Emons G.** Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)- mediated activation of phosphotyrosine phosphatase. *Endocrinology* 142: 2369-2380, 2001.

**Hafner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A, Pippig S, Lohse M, Ueffing M, Kolch W.** Mechanism of inhibition of Raf-1 by protein kinase A. *Mol Cell Biol* 14: 6696-6703, 1994.

**Hallbook F.** Evolution of the vertebrate neurotrophin and Trk receptor gene families. *Curr Opin Neurobiol* 9: 616-612, 1999.

**Han XB and Conn PM.** The role of protein kinases A and C pathways in the regulation of mitogen-activated protein kinase activation in response to gonadotropin-releasing hormone receptor activation. *Endocrinology* 140: 2241-2251, 1999.

**Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA and Connelly PA.** Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. *J Biol Chem* 271: 695-701, 1996.

**Hansra G, Bornancin F, Whelan R, Hemmings BA, Parker PJ.** 12-O-Tetradecanoylphorbol-13-acetate-induced dephosphorylation of protein kinase Calpha correlates with the presence of a membrane-associated protein phosphatase 2A heterotrimer. *J Biol Chem* 271: 32785-32788, 1996.

**Hawes BE, Barnes S and Conn PM.** Cholera toxin and pertussis toxin provoke differential effects on luteinizing hormone release, inositol phosphate production, and gonadotropin-releasing hormone (GnRH) receptor binding in the gonadotrope: evidence for multiple guanyl nucleotide binding proteins in GnRH action. *Endocrinology* 132: 2124-2130, 1993.

**Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ.** Phosphatidylinositol 3-kinase is an early intermediate in the G beta gamma-mediated mitogen-activated protein kinase signaling pathway. *J Biol Chem* 271: 12133-12136, 1996.

**Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, Simpson LC.** GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. *Science* 266: 1062-1064, 1994.

**Herbert JM, Augereau JM, Gleye J and Maffrand JP.** Chelerythrine is a potent and specific inhibitor of protein kinase C. *Biochem Biophys Res Commun* 172: 993-999, 1990.

**Herrmann C, Martin GA, Wittinghofer A.** Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. *J Biol Chem* 270: 2901-2905, 1995.

**Hilborn MD, Vaillancourt RR and Rane SG.** Growth factor receptor tyrosine kinases acutely regulate neuronal sodium channels through the src signaling pathway. *J Neurosci* 18: 590-600, 1998.

**Hofmann J.** The potential for isoenzyme-selective modulation of protein kinase C. *FASEB J* 11: 649-669, 1997.

**Holen T and Mobbs CV.** Lobotomy of genes: use of RNA interference in Neuroscience. *Neuroscience* 126: 1-7, 2004.

**Horn JP, Fatherazi S, Stofer WD.** Differential projections of B and C sympathetic axons in peripheral nerves of the bullfrog. *J Comp Neurol* 278: 570-580, 1988.

**Horn JP and Stofer WD.** Spinal origins of preganglionic B and C neurons that innervate paravertebral sympathetic ganglia nine and ten of the bullfrog. *J Comp Neurol* 268: 71-83, 1988.

**Hsieh KP and Martin TF.** Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins Gq and G11. *Mol Endocrinol* 6:1673-1681, 1992.

**Huang EJ and Reichardt LF.** Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci* 24: 677-736, 2001.

**Huang EJ and Reichardt LF.** Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 72: 609-642, 2003.

**Iida N, Namikawa K, Kiyama H, Ueno H, Nakamura S, Hattori S.** Requirement of Ras for the activation of mitogen-activated protein kinase by calcium influx, cAMP, and neurotrophin in hippocampal neurons. *J Neurosci* 21: 6459-6466, 2001.

**Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T.** Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. *J Clin Endocrinol Metab* 81: 3249-3253, 1996.

**Impey S, Obrietan K, Wong ST, Poser S, Yano S, Wayman G, Deloulme JC, Chan G and Storm DR.** Cross talk between ERK and PKA is required for Ca<sup>2+</sup> stimulation of CREB- dependent transcription and ERK nuclear translocation. *Neuron* 21: 869-883, 1998.

**Impey S, Obrietan K, Storm DR.** Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. *Neuron* 23: 11-14, 1999.

**Ivanoff AY and Smith PA.** In vivo activity of B- and C-neurons in the paravertebral sympathetic ganglia of the bullfrog. *J Physiol* 485 (Pt 3): 797-815, 1995.

**Jan YN, Jan LY and Kuffler SW.** A peptide as a possible transmitter in sympathetic ganglia of the frog. *Proc Natl Acad Sci USA* 76: 1501-1505, 1979.

**Jan YN, Jan LY and Kuffler SW.** Further evidence for peptidergic transmission in sympathetic ganglia. *Proc Natl Acad Sci USA* 77: 5008-5012, 1980a.

**Jan YN, Jan LY and Kuffler SW.** Peptidergic transmitters in synaptic boutons of sympathetic ganglia. *Nature* 288: 380-382, 1980b.

**Jan LY and Jan YN.** Peptidergic transmission in sympathetic ganglia of the frog. *J Physiol* 327: 219-246, 1982.

**Janovick JA and Conn PM.** A cholera toxin-sensitive guanyl nucleotide binding protein mediates the movement of pituitary luteinizing hormone into a releasable pool: loss of this event is associated with the onset of homologous desensitization to gonadotropin-releasing hormone. *Endocrinology* 132: 2131-2135, 1993.

**Janovick JA and Conn PM.** Gonadotropin-releasing hormone (GnRH)-receptor coupling to inositol phosphate and prolactin production in GH3 cells stably transfected with rat GnRH receptor complementary deoxyribonucleic acid. *Endocrinology* 135: 2214-2219, 1994.

**Jassar BS, Pennefather PS and Smith PA.** Changes in sodium and calcium channel activity following axotomy of B- cells in bullfrog sympathetic ganglion. *J Physiol* 472: 203-231, 1993.

**Jassar BS, Pennefather PS and Smith PA.** Changes in potassium channel activity following axotomy of B-cells in bullfrog sympathetic ganglion. *J Physiol (Lond)* 479 (Pt 3): 353-370, 1994.

**Jobling P and Horn JP.** In vitro relation between preganglionic sympathetic stimulation and activity of cutaneous glands in the bullfrog. *J Physiol* 494: 287-296, 1996.

**Jones SW.** Muscarinic and peptidergic excitation of bullfrog sympathetic neurons. *J Physiol* 366: 63-87, 1985.

**Jones SW.** Sodium currents in dissociated bull-frog sympathetic neurones. *J Physiol (Lond)* 389: 605-662, 1987.

**Jones SW, Adams PR, Brownstein MJ, Rivier JE.** Teleost luteinizing hormone-releasing hormone: action on bullfrog sympathetic ganglia is consistent with role as neurotransmitter. *J Neurosci* 4: 420-429, 1984.

**Jones SW and Elmslie KS.** Separation and modulation of calcium currents in bullfrog sympathetic neurons. *Can J Physiol Pharmacol* 70 [Suppl]: S56-S63, 1992.

**Jones SW and Jacobs LS.** Dihydropyridine actions on calcium currents of frog sympathetic neurons. *J Neurosci* 10: 2261-2267, 1990.

**Jones SW and Marks TN.** Calcium currents in bullfrog sympathetic neurons. I. Activation kinetics and pharmacology. *J Gen Physiol* 94: 151-167, 1989a.

**Jones SW and Marks TN.** Calcium currents in bullfrog sympathetic neurons. II. Inactivation. *J Gen Physiol* 94: 169-182, 1989b.

**Kafitz KW, Rose CR, Thoenen H, Konnerth A.** Neurotrophin-evoked rapid excitation through TrkB receptors. *Nature* 401: 918-921, 1999.

**Kakar SS, Malik MT and Winters SJ.** Gonadotropin-releasing hormone receptor: cloning, expression and transcriptional regulation. *Prog Brain Res* 141: 129-147, 2002.

**Kaplan DR and Stephens RM.** Neurotrophin signal transduction by the Trk receptor. *J Neurobiol* 25: 1404-1407, 1994.

**Kaplan DR and Miller FD.** Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol* 10: 381-391, 2000.

**Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE and Graybiel AM.** A family of cAMP-binding proteins that directly activate Rap1. *Science* 282: 2275-2279, 1998.

**Khorkova O and Golowasch J.** Neuromodulators, Not Activity, Control Coordinated Expression of Ionic Currents. *Journal of Neuroscience* 27: 8709-8718, 2007.

**Kim C, Vigil D, Anand G, Taylor SS.** Structure and dynamics of PKA signaling proteins. *Eur J Cell Biol* 87: 651-654, 2006.

**King JA and Millar RP.** Comparative aspects of luteinizing hormone-releasing hormone structure and function in vertebrate phylogeny. *Endocrinology* 106: 707-117, 1980.

**Klausen C, Chang JP, Habibi HR.** Multiplicity of gonadotropin-releasing hormone signaling: a comparative perspective. *Prog Brain Res* 141: 111-128, 2002.

**Koch CA, Anderson D, Moran MF, Ellis C and Pawson T.** SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. *Science* 252: 668-674, 1991.

**Koch WJ, Hawes BE, Allen LF, Lefkowitz RJ.** Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. *Proc Natl Acad Sci USA* 91: 12706-12710, 1994.

**Kohout TA and Lefkowitz RJ.** Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol* 63: 9-18, 2003.

**Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR.** Protein kinase C alpha activates RAF-1 by direct phosphorylation. *Nature* 364: 249-252, 1993.

**Kovalchuk Y, Holthoff K, Konnerth A.** Neurotrophin action on a rapid timescale. *Curr Opin Neurobiol* 14: 558-563, 2004.

**Krasilnikov MA.** Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. *Biochemistry (Mosc)* 65: 59-67, 2000.

**Kuphal D, Janovick JA, Kaiser UB, Chin WW and Conn PM.** Stable transfection of GH3 cells with rat gonadotropin-releasing hormone receptor complementary deoxyribonucleic acid results in expression of a receptor coupled to cyclic adenosine 3', 5'- monophosphate-dependent prolactin release via a G-protein. *Endocrinology* 135: 315-320, 1994.

**Kurenyy DE, Chen H and Smith PA.** Effects of muscarine on K(+)-channel currents in the C-cells of bullfrog sympathetic ganglion. *Brain Res* 658: 239-251, 1994.

**Lanscaster B and Pennefather P.** Potassium currents evoked by brief depolarizations in bull-frog sympathetic ganglion cells. *J Physiol* 387: 519-548, 1987.

**Laporte SA, Oakley RH, Holt JA, Barak LS, Caron MG.** The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. *J Biol Chem* 275: 23120-23126, 2000.

**Lauder JM.** Neurotransmitters as growth regulatory signals: role of receptors and second messengers. *Trends Neurosci* 16:233-240, 1993.

**Lazarovici P, Jiang H, Fink D Jr.** The 38-amino-acid form of pituitary adenylate cyclase-activating polypeptide induces neurite outgrowth in PC12 cells that is dependent on protein kinase C and extracellular signal-regulated kinase but not on protein kinase A, nerve growth factor receptor tyrosine kinase, p21(ras) G protein, and pp60(c-src) cytoplasmic tyrosine kinase. *Mol Pharmacol* 54: 547-558, 1998.

**Lei S, Dryden WF, Smith PA.** Regulation of N- and L- type Calcium Channels in Adult Frog Sympathetic Ganglion B Cells by Nerve Growth Factor In Vitro and In Vivo. *J Neurophysiol* 78: 3359-3370, 1997.

**Lei S, Dryden WF, Smith PA.** Involvement of Ras/MAP kinase in the regulation of Ca<sup>2+</sup> channels in adult bullfrog sympathetic neurons by nerve growth factor. *J Neurophysiol* 80: 1352-1361, 1998.

**Lei S, Dryden WF, Smith PA.** Nerve growth factor regulates sodium but not potassium channel currents in sympathetic b neurons of adult bullfrogs. *J Neurophysiol* 86: 641-650, 2001.

**Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, Schlessinger J.** Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. *Nature* 376: 737-745, 1995.

**Levi-Montalcini R and Hamburger V.** Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. *J Exp Zool* 116: 321-361, 1951.

**Levi-Montalcini R.** The nerve growth factor 35 years later. *Science* 237: 1154-1162, 1987.

**Levine ES, Crozier RA, Black IB, Plummer MR.** Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. *Proc Natl Acad Sci USA* 95: 10235-10239, 1998.

**Levine ES, Dreyfus CF, Black IB and Plummer MR.** Differential effects of NGF and BDNF on voltage-gated calcium currents in embryonic basal forebrain neurons. *J Neurosci* 15: 3084-3091, 1995.

**Lewin GR.** Neurotrophins and the specification of neuronal phenotype. *Philos Trans R Soc Lond B Biol Sci* 351: 405-411, 1996.

**Lewin GR, Ritter AM, Mendell LM.** On the role of nerve growth factor in the development of myelinated nociceptors. *J Neuro Sci* 12:1896-1905, 1992.

**Lewis TS, Shapiro PS, Ahn NG.** Signal transduction through MAP kinase cascades. *Adv Cancer Res* 74: 49-139, 1998.

**Lhuillier L and Dryer SE.** Developmental regulation of neuronal K(Ca) channels by TGFbeta1: an essential role for PI3 kinase signaling and membrane insertion. *J Neurophysiol* 88: 954-964, 2002.

**Libet B, Chichibu S, Tosaka T.** Slow synaptic responses and excitability in sympathetic ganglia of the bullfrog. *J Neurophysiol* 31: 383-395, 1968.



**Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F.** GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 260: 1130-1132, 1993.

**Lindsay RM.** Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview. *Philos Trans R Soc Lond B Biol* 351: 365-373, 1996.

**Liu J, Lin A.** Role of JNK activation in apoptosis: A double-edge sword. *Cell Research* 15: 36-42, 2005.

**Loeb DM, Maragos J, Martin-Zanca D, Chao MV, Parada LF, Greene LA.** The trk proto-oncogene rescues NGF responsiveness in mutant NGF-nonresponsive PC12 cell lines. *Cell* 66: 961-966, 1991.

**Lohof AM, Nancy YI, and Poo M-m.** Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. *Nature*: 363(6427):350-3, 1993.

**Lohse MJ, Andexinger S, Pitcher J, Trukawinski S, Codina J, Faure JP, Caron MG, Lefkowitz RJ.** Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems. *J Biol Chem* 267: 8558-8564, 1992.

**Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ.** beta-Arrestin: a protein that regulates beta-adrenergic receptor function. *Science* 248: 1547-1550, 1990.

**Lopez-Illasaca M, Crespo P, Pellici PG, Gutkind JS and Wetzker R.** Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. *Science* 275: 394-397, 1997.

**Lu VB, Ford CP, Dryden WF and Smith PA.** Regulation of Sodium Channels by NGF but not LHRH, the Role of PI3K. *Soc Neurosci Abs* 28: 743.1, 2002.

**Liu Y, Graham C, Li A, Fisher RJ, Shaw S.** Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only

activation loop phosphorylation is critical to in vivo nuclear-factor-kappaB induction. *Biochem J* 361: 255-265, 2002.

**Luttrell LM.** Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. *Can J Physiol Pharmacol* 80: 375-382, 2002.

**Ma W and Quirion R.** Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. *Pain* 99: 175-184, 2002.

**Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ.** Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. *J Biol Chem* 272: 4378-4383, 1997.

**Marinissen MJ, Servitja JM, Offermanns S, Simon MI, Gutkind JS.** Thrombin protease-activated receptor-1 signals through Gq- and G13-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. *J Biol Chem* 278: 46814-46825, 2003.

**Marrion NV, Zucker RS, Marsh SJ and Adams PR.** Modulation of M-current by intracellular Ca<sup>2+</sup>. *Neuron* 6: 533-545, 1991.

**Martin-Caraballo M and Dryer SE.** Glial cell line-derived neurotrophic factor and target-dependent regulation of large-conductance KCa channels in developing chick lumbar motoneurons. *J Neurosci* 22: 10201-10208, 2002.

**Matthies HJ, Palfrey HC, Hirning LD and Miller RJ.** Down regulation of protein kinase C in neuronal cells: effects on neurotransmitter release. *J Neurosci* 7: 1198-1206, 1987.

**Mattingly RR and Macara IG.** Phosphorylation-dependent activation of the Ras-GRF/CDC25Mm exchange factor by muscarinic receptors and G-protein beta gamma subunits. *Nature* 382: 268-272.

**McArdle CA, Franklin J, Green L and Hislop JN.** The gonadotrophin-releasing hormone receptor: signalling, cycling and desensitisation. *Arch Physiol Biochem* 110: 113-122, 2002.

**McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS.** G-protein signaling: back to the future. *Cell Mol Life Sci* 62: 551-577, 2005.

**McKeon TW and Zigmond RE.** Vasoactive intestinal peptide and secretin produce long-term increases in tyrosine hydroxylase activity in the rat superior cervical ganglion. *Brain Res* 607: 345-348, 1993.

**Millar RP.** GnRHs and GnRH receptors. *Animal Reprod Sci* 88:5-28, 2005.

**Millar RP and King JA.** Structural and functional evolution of gonadotropin-releasing hormone. *Int Rev Cytol* 106: 149-182, 1987.

**Millar RP, King JA, Davidson JS, Milton RC.** Gonadotrophin-releasing hormone--diversity of functions and clinical applications. *S Afr Med J* 72: 748-755, 1987.

**Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R, Faurholm B, Scobie G, Kuestner R, Terasawa E and Katz A.** A novel mammalian receptor for the evolutionarily conserved type II GnRH. *Proc Natl Acad Sci U S A* 98: 9636-9641, 2001.

**Miller WE and Lefkowitz RJ.** Expanding roles for  $\beta$ -arrestins as scaffolds and adapters in GPCR signaling and trafficking. *Curr Opin Cell Biol* 13: 139-145, 2001.

**Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, Schellerer M, Philipp A, Kolch W.** Negative regulation of Raf-1 by phosphorylation of serine 621. *Mol Cell Biol* 16: 5409-5418, 1996.

**Mitchell R, Sim PJ, Leslie T, Johnson MS, Thomson FJ.** Activation of MAP kinase associated with the priming effect of LHRH. *J Endocrinol* 140: R15-R18, 1994.

**Mitsui H, Takuwa N, Kurokawa K, Exton JH, Takuwa Y.** Dependence of activated Galph12-induced G1 to S phase cell cycle progression on both Ras/mitogen-activated protein kinase and Ras/Rac1/Jun N-terminal kinase cascades in NIH3T3 fibroblasts. *J Biol Chem* 272: 4904-4910, 1997.

**Miyamoto K, Hasegawa Y, Nomura M.** Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. *Proc Natl Acad Sci USA* 81: 3874-3878, 1984.

**Mulvaney JM, Zhang T, Fewtrell C, Roberson MS.** Calcium influx through L-type channels is required for selective activation of extracellular signal-regulated kinase by gonadotropin-releasing hormone. *J Biol Chem* 274: 29796-29804, 1999.

**Murakami A, Yajima T, Sakuma H, McLaren MJ, Inana G.** X-arrestin: a new retinal arrestin mapping to the X chromosome. *FEBS Lett* 334: 203-209, 1993.

**Murphy TH, Worley PF, Baraban JM.** L-type voltage-sensitive calcium channels mediate synaptic activation of immediate early genes. *Neuron* 7: 625-635, 1991.

**Naor Z, Benard O, Seger R.** Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. *Trends Endocrinol Metab* 11: 91-99, 2000.

**Naor Z, Harris D, Shacham S.** Mechanism of GnRH receptor signaling: combinatorial cross-talk of Ca<sup>2+</sup> and protein kinase C. *Front Neuroendocrinol* 19: 1-19, 1998a.

**Naor Z, Harris D, Shacham S.** Mechanism of GnRH receptor signaling: combinatorial cross-talk of Ca<sup>2+</sup> and protein kinase C. *Front Neuroendocrinol* 19: 1-19, 1998b.

**Newton AC.** Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. *Chem Rev* 101: 2353-2364, 2001.

**Newton AC.** Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. *Biochem J* 370: 361-371, 2003.

**Nilsson AS, Fainzilber M, Falck P, Ibanez CF.** Neurotrophin-7: a novel member of the neurotrophin family from the zebrafish. *FEBS Lett* 424: 285-290, 1998.

**Nishi S, Soeda H, Koketsu K.** Studies on sympathetic B and C neurons and patterns of preganglionic innervation. *J Cell Comp Physiol* 66: 19-32, 1965.

**Nishina H, Wada T, Katada T.** Physiological roles of SAPK/JNK signaling pathway. *J Biochem* 136: 123-126, 2004.

**Offermanns S, Laugwitz KL, Spicher K, Schultz G.** G proteins of the G12 family are activated via thromboxane A<sub>2</sub> and thrombin receptors in human platelets. *Proc Natl Acad Sci USA* 91: 504-508, 1994.

**Ohno S and Nishizuka Y.** Protein kinase C isotypes and their specific functions: prologue. *J Biochem (Japan)* 132: 509-511, 2002.

**Orr JW and Newton AC.** Requirement for negative charge on "activation loop" of protein kinase C. *J Biol Chem* 269: 27715-27718, 1994.

**Parekh DB, Ziegler W, Parker PJ.** Multiple pathways control protein kinase C phosphorylation. *EMBO J* 19: 496-503, 2000.

**Pawson T and Nash P.** Protein-protein interactions define specificity in signal transduction. *Genes Dev* 14: 1027-1047, 2000.

**Pears C, Stabel S, Cazaubon S, Parker PJ.** Studies on the phosphorylation of protein kinase C- $\alpha$ . *Biochem J* 283: 515-518, 1992.

**Peng YY and Horn JP.** Continuous repetitive stimuli are more effective than bursts for evoking LHRH release in bullfrog sympathetic ganglia. *J Neurosci* 11: 85-95, 1991.

**Pennefather P, Lancaster B, Adams PR, Nicoll RA.** Two distinct Ca-dependent K currents in bullfrog sympathetic ganglion cells. *Proc Natl Acad Sci USA* 82: 3040-3044, 1985.

**Peterziel H, Unsicker K, Krieglstein K.** TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane. *J Cell Biol* 159: 157-167, 2002.

**Petrov T, Shapiro Y, Baker C, Duff JP, Gordon T and Smith PA.** Peripheral Target Contact Regulates Ca<sup>2+</sup> Channels in the Cell Bodies of Bullfrog Sympathetic Ganglion B-Neurons. *Autom Neurosci* 89: 74-85, 2001.

**Pfaffinger PJ, Leibowitz MD, Subers EM, Nathanson NM, Almers W and Hille B.** Agonists that suppress M-current elicit phosphoinositide turnover and Ca<sup>2+</sup> transients, but these events do not explain M-current suppression. *Neuron* 1: 477-484, 1988.

**Pierce KL, Luttrell LM, Lefkowitz RJ.** New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. *Oncogene* 20: 1532-1539, 2001.

**Pitcher J, Lohse MJ, Codina J, Caron MG, Lefkowitz RJ.** Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. *Biochemistry* 31: 3193-3197, 1992.

**Pollock JD, Krempin M and Rudy B.** Differential effects of NGF, FGF, EGF, cAMP, and dexamethasone on neurite outgrowth and sodium channel expression in PC12 cells. *J Neurosci* 10: 2626-2637, 1990.

**Pollock JD and Rane SG.** p21ras signaling is necessary but not sufficient to mediate neurotrophin induction of calcium channels in PC12 cells. *J Biol Chem* 271: 8008-8014, 1996.

**Popp RL, Velasquez O, Bland J, Hughes P.** Characterization of protein kinase C isoforms in primary cultured cerebellar granule cells. *Brain Res* 1083: 70-84, 2006.

**Poteryaev D, Titievsky A, Sun YF, Thomas-Crusells J, Lindahl M, Billaud M, Arumae U, Saarma M.** GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor alpha1. *FEBS Lett* 463: 63-66, 1999.

**Pouyssegur J, Volmat V, Lenormand P.** Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. *Biochem Pharmacol* 64: 755-763, 2002.

**Radhika V and Dhanasekaran N.** Transforming G proteins. *Oncogene* 20: 1607-1614, 2001.

**Rajagopal R, Chen ZY, Lee FS, Chao MV.** Transactivation of Trk Neurotrophin Receptors by G-Protein-Coupled Receptor Ligands Occurs on Intracellular Membranes. *Journal of Neuroscience* 24: 6650-6658, 2004.

**Raman M, Chen W, Cobb MH.** Differential regulation and properties of MAPKs. *Oncogene* 26: 3100-3112, 2007.

**Redburn D and Schousboe A.** *Neurotrophic Activity of GABA During Development* Alan R. Liss, New York, 1987.

**Reichardt LF and Farinas I.** Neurotrophic factors and their receptors. Roles in neuronal development and function. In *Molecular and Cellular Approaches to Neural Development*, ed. WM Cowan, TM Jessell, SL Zipursky, pp. 220-263. New York: Oxford Univ. Press, 1997.

**Reiss N, Llevi LN, Shacham S, Harris D, Seger R and Naor Z.** Mechanism of mitogen-activated protein kinase activation by gonadotropin-releasing hormone in the pituitary of alphaT3-1 cell line: differential roles of calcium and protein kinase C. *Endocrinology* 138: 1673-1682, 1997.

**Rhee SG and Choi KD.** Regulation of inositol phospholipid-specific phospholipase C isozymes. *J Biol Chem* 267: 12393-12396, 1992.

**Roberson MS, Misra-Press A, Laurance ME, Stork PJ, Maurer RA.** A role for mitogen-activated protein kinase in mediating activation of the glycoprotein hormone

alpha-subunit promoter by gonadotropin-releasing hormone. *Mol Cell Biol* 15: 3531-3539, 1995.

**Roux PP and Barker PA.** Neurotrophin signalling through the p75 neurotrophin receptor. *Prog Neurobiol* 67: 203-233, 2002.

**Ryves WJ, Evans AT, Olivier AR, Parker PJ and Evans FJ.** Activation of the PKC-isotypes alpha, beta 1, gamma, delta and epsilon by phorbol esters of different biological activities. *FEBS Lett* 288: 5-9, 1991.

**Sala F.** Activation kinetics of calcium currents in bull-frog sympathetic neurones. *J Physiol (Lond)* 437: 221-238, 1991.

**Sariola H and Saarma M.** Novel functions and signaling pathways for GDNF. *J Cell Sci* 116: 3855-3862, 2003.

**Seger R, Krebs EG.** The MAPK signaling cascade. *FASEB J.* 9: 726-735, 1995.

**Selyanko AA, Smith PA, Zidichouski JA.** Effects of muscarine and adrenaline on neurones from *Rana pipiens* sympathetic ganglia. *J Physiol (Lond)* 425: 417-500, 1990.

**Shah BH, Soh JW, Catt KJ.** Dependence of gonadotropin-releasing hormone-induced neuronal MAPK signaling on epidermal growth factor receptor transactivation. *J Biol Chem* 278: 2866-2875, 2003.

**Shinohara T, Dietzschold B, Craft CM, Wistow G, Early JJ, Donoso LA, Horwitz J, Tao R.** Primary and secondary structure of bovine retinal S antigen (48-kDa protein). *Proc Natl Acad Sci USA* 84:6975-6979, 1987.

**Shirai Y and Saito N.** Activation mechanisms of protein kinase C: maturation, catalytic activation, and targeting. *J Biochem (Tokyo)* 132: 663-668, 2002.



**Sim PJ, Wolbers WB, Mitchell R.** Activation of MAP kinase by the LHRH receptor through a dual mechanism involving protein kinase C and a pertussis toxin-sensitive G protein. *Mol Cell Endocrinol* 112: 257-263, 1995.

**Smith PA.** Amphibian sympathetic ganglia: an owner's and operator's manual. *Prog Neurobiol* 43: 439-510, 1994.

**Smith PA.** Methods for studying neurotransmitter transduction mechanisms. *J Pharmacol Toxicol Methods* 33: 63-73, 1995.

**Spoerri PE.** Neurotrophic effects of GABA in cultures of embryonic chick brain and retina. *Synapse* 22: 11-22, 1988.

**Sofroniew MV, Howe CL, Mobley WC.** Nerve growth factor signaling, neuroprotection, and neural repair. *Annu Rev Neurosci* 24: 1217-1281, 2001.

**Soltoff SP, Rabin SL, Cantley LC, Kaplan DR.** Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. *J Biol Chem* 267: 17472-17477, 1992.

**Song M-S, Posse de Chaves E.** Inhibition of rat sympathetic neuron apoptosis by ceramide. Role of p75NTR in ceramide generation. *Neuropharmacol* 45: 1130-1150, 2003.

**Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, Glass DJ, Masiakowski P, Furth ME, Valenzuela DM.** trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. *Cell* 65: 885-893, 1991.

**Stanislaus D, Janovick JA, Brothers S, Conn PM.** Regulation of G (q/11) alpha by the gonadotropin-releasing hormone receptor. *Mol Endocrinol* 11: 738-746, 1997.

**Stenkowski PL, Tse FW, Peuckmann V, Ford CP, Colmers WF, Smith PA.** ATP-Inhibition of M Current in Frog Sympathetic Neurons Involves Phospholipase C but Not Ins P(3), Ca(2+), PKC, or Ras. *J Neurophysiol* 88: 277-288, 2002.

**Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT.** Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. *Science* 279: 710-714, 1998.

**Stephens LR, Eguinoa A, Erdjument-Bromage H, Lui M, Cooke F, Coadwell J, Smrcka AS, Thelen M, Cadwallader K, Tempst P, Hawkins PT.** The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. *Cell* 89: 105-114, 1997.

**Stephens RM, Loeb DM, Copeland TD, Pawson T, Greene LA, Kaplan DR.** Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. *Neurons* 12: 691-705, 1994.

**Stojilkovic SS and Catt KJ.** Novel aspects of GnRH-induced intracellular signaling and secretion in pituitary gonadotrophs. *J Endocrinol* 7: 739-757, 1995.

**Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT.** Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. *Science* 277: 567-570, 1997.

**Stork PJ and Schmitt JM.** Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. *Trends Cell Biol* 12: 258-266, 2002.

**Sugden PH and Clerk A.** Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. *Cell Signal* 9: 337-351, 1997.

**Sundaresan S, Colin IM, Pestell RG and Jameson JL.** Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone: evidence for the involvement of protein kinase C. *Endocrinology* 137: 304-311, 1996.

**Takeda H, Matozaki T, Takada T, Noguchi T, Yamao T, Tsuda M, Ochi F, Fukunaga K, Inagaki K, Kasuga M.** PI 3-kinase gamma and protein kinase C-zeta mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. *EMBO J* 18: 386-395, 1999.

**Takei N, Numakawa T, Kozaki S, Sakai N, Endo Y, Takahashi M, Hatanaka H.** Brain-derived neurotrophic factor induces rapid and transient release of glutamate through the non-exocytotic pathway from cortical neurons. *J Biol Chem* 273(42):27620-4, 1998.

**Tanoue T, Adachi M, Moriguchi T, Nishida E.** A conserved docking motif in MAP kinases common to substrates, activators and regulators. *Nat Cell Biol* 2: 110-116, 2000.

**Tasken K and Aandahl EM.** Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol Rev* 84: 137-167, 2004.

**Taylor SS, Haste NM, Ghosh G.** PKR and eIF2alpha: integration of kinase dimerization, activation, and substrate docking. *Cell* 122: 823-825.

**Thorne R and Horn JP.** Role of ganglionic cotransmission in sympathetic control of the isolated bullfrog aorta. *J Physiol* 498: 201-214, 1997.

**Tilakaratne N and Sexton PM.** G-Protein-coupled receptor-protein interactions: basis for new concepts on receptor structure and function. *Clin Exp Pharmacol Physiol* 32: 979-987, 2005.

**Tokimasa T and Akasu T.** ATP regulates muscarine-sensitive potassium current in dissociated bull-frog primary afferent neurones. *J Physiol* 426: 241-264, 1990.

**Trupp M, Scott R, Whittemore SR, Ibanez CF.** Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. *J Biol Chem* 274: 20885-20894, 1999.

**Tsui-Pierchala BA, Milbrandt J, Johnson EM Jr.** NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons. *Neurons* 33: 261-273, 2002.

**Tsygankova OM, Kupperman E, Wen W, Meinkoth JL.** Cyclic AMP activates Ras. *Oncogene* 19: 3609-3615, 2000.

**Ulloa-Aguirre A, Stanislaus D, Arora V, Vaananen J, Brothers S, Janovick JA and Conn PM.** The third intracellular loop of the rat gonadotropin-releasing hormone receptor couples the receptor to Gs- and G(q/11)-mediated signal transduction pathways: evidence from loop fragment transfection in GGH3 cells. *Endocrinology* 139: 2472-2478, 1998.

**Voet D and Voet JD.** Molecular Physiology. In *Biochemistry* pp. 1196-1309, 1995.

**Voyno-Yasenetskaya TA, Faure MP, Ahn NG, Bourne HR.** Galpha12 and Galpha13 regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells. *J Biol Chem* 271:21081-21087, 1996.

**Vossler MR, Yao H, York RD, Pan MG, Rim CS and Stork PJ.** cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. *Cell* 89: 73-82, 1997.

**Werz MA, Elmslie KS, Jones SW.** Phosphorylation enhances inactivation of N-type calcium channel current in bullfrog sympathetic neurons. *Pflugers Arch* 424: 538-545, 1993.

**Whitman M, Downes CP, Keeler M, Keller T, Cantley L.** Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. *Nature* 332: 644-666, 1988.

**Widmann C, Gibson S, Jarpe MB, Johnson GL.** Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. *Physiol Rev* 79: 143-180, 1999.

**Whitmarsh AJ and Davis RJ.** Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. *Trends Biochem Sci* 23: 481-485, 1998.

**Wolff JR, Joo F, Dames W.** Plasticity in dendrites shown by continuous GABA administration in superior cervical ganglion of adult rat. *Nature* 274: 72-74, 1978.

**Wong KV, Ford CP, Lu VB, Posse de Chaves E, Smith PA, Dryden WF.** Akt regulation of Na<sup>+</sup> channels and ras/MAPK regulation of Ca<sup>2+</sup> channels in adult sympathetic neurons by the peptide, LHRH and the neurotrophin, NGF. *Society for Neuroscience Abstracts* 622.9, 2006.

**Woodgett JR, Hunter T.** Immunological evidence for two physiological forms of protein kinase C. *Mol Cell Biol* 7: 85-96, 1987.

**Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW.** Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3', 5'-monophosphate. *Science* 262: 1065-1069, 1993.

**Xiang Y, Li Y, Zhang Z, Cui K, Wang S, Yuan XB, Wu CP, Poo MM, Duan S.** Nerve growth cone guidance mediated by G protein-coupled receptors. *Nat Neurosci* 5: 843-848, 2002.

**Yamaki K, Takahashi Y, Sakuragi S, Matsubara K.** Molecular cloning of the S-antigen cDNA from bovine retina. *Biochem Biophys Res Commun* 142: 904-910, 1987.

**Yang F, Feng L, Zheng F, Johnson SW, Du J, Shen L, Wu CP, Lu B.** GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. *Nat Neurosci* 4: 1071-1078, 2001.

**Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y and Matsuda Y.** Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. *J Biol Chem* 268: 25846-25856, 1993.

**Yuan J and Yankner BA.** Apoptosis in the nervous system. *Nature* 407: 802-809, 2000.

**Young SW, Dickens M, Tavare JM.** Differentiation of PC12 cells in response to a cAMP analogue is accompanied by sustained activation of mitogen-activated protein kinase. Comparison with the effects of insulin, growth factors and phorbol esters. *FEBS Lett* 338: 212-216, 1994.

**Zhang W and Liu HT.** MAPK signal pathways in the regulation of cell proliferation in mammalian cells. *Cell Research* 12:9-18, 2002.